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The epithelial layers of the small intestine (SI) and large intestine (LI) are generated via self-
renewal and differentiation of tissue-specific stem cells (SCs). Failure of intestinal SCs to 
respond properly to proliferation and differentiation signals can lead to the formation of cancer, 
almost exclusively found in the LI in humans. We hypothesize that there are distinct resident SCs 
in the SI versus LI leading to an increased frequency of human LI (colon) cancer. While fleeting 
observations of differences between SI and LI have been made in the past, a robust study of the 
origin of their differences has yet to be done. Here we show dramatic intrinsic differences 
between normal human SI and LI SCs that may have important implications for the disparity in 
their susceptibilities to cancer. Primary human fetal SI and LI cells were isolated and expanded 
in vitro using conditions that selected for SCs. Flow cytometry and limiting dilution analysis 
indicated differential SC marker expression as well as disparate populations of colony-forming 
cells. Gene array analysis showed separate hierarchical clustering and differential expression of 
transcripts involved in differentiation, proliferation and disease pathways of the SI and LI. Using 
a three-dimensional in vitro differentiation assay, SI and LI SCs formed organoids with 
architecture and cellular hierarchy similar to that found in vivo. Immunostaining and real-time 
PCR indicated that both SI and LI SCs retain the ability to differentiate into mature cells of the 
intestine. We also found that well-known proliferation and differentiation pathways in SI- and 
LI-derived organoids responded differently when exposed to the same exogenous stimuli. 
SMALL AND LARGE INTESTINAL STEM CELLS AND THEIR RELATION TO 
CANCER 
Julie Marie Cramer, MS, PhD 
University of Pittsburgh, 2013
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Notably, upon exposure to differentiation cues, an expected decrease in SC marker LGR5 in SI 
SCs was met with an unexpected increase in LI SCs. We also demonstrate similarities between 
human LI SCs and colon cancer SCs not present in SI SCs, supporting the notion that normal 
intestinal SCs are the cell of origin of cancer. Our characterization of human fetal SI and LI SCs 
revealed critical intrinsic differences that may affect their susceptibility to diseases such as 
cancer. Further elucidation of pathway differences may allow the exploitation of protective 
mechanisms to prevent or treat human colon cancer.  
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1.0  INTRODUCTION 
Colon cancer, or cancer of the large intestine (LI), remains third in the list of estimated new 
cases and estimated deaths when considering all cancer sites 
1
. While its 5-year survival rate is 
90.3% if diagnosed at the local stage, this drops to 12.5% at the metastatic stage 
2
. Current 
treatments for metastatic disease, focused on treating rapidly dividing cells, can lead to toxicity 
and ultimately poor patient outcome. The genetic model for sporadic colorectal tumorigenesis is 
defined as an accumulation of mutations and modifications, building on one another with 
increased chromosomal instability which ultimately ends in the formation of a carcinoma and 
often times metastasis 
3
. These initial mutations are likely to occur in a population of cells that 
already possess many advantageous characteristics for cancer cells. Therefore, recent evidence 
has implicated the normal intestinal SC as the cell of origin of LI cancer, which seems to follow 
a similar differentiation pattern compared to normal tissue 
4
. Only in recent years have we begun 
to understand the intricate niche of the normal intestinal SC and its regulation 
5
. Our current 
knowledge of intestinal SCs and their niche has largely come from experiments performed in the 
SI with the assumption that the results would likely hold true in the LI. However, based on their 
functional and structural differences in vivo, it is likely that their homeostatic mechanisms and 
response to transformative events differ and are reflected in their cancer incidence, mortality and 
5-year survival rates (Table 1) 2.  
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Table 1: Small versus large intestinal cancer statistics 
Statistic Small Intestine Large Intestine 
Incidence rate* 2.1 45 
Mortality* 0.4 16.4 
5-yr survival rate with diagnosis at 
metastatic stage 42.1% 12.5% 
*per 100,000 per year 
Statistics were taken from the National Cancer Institute’s SEER Stat Fact Sheets  
1.1 INTESTINAL ORGANIZATION 
A myriad of cells contribute to the normal function and maintenance of adult tissues. Some cells, 
are terminally differentiated and will die serving the tissue. Other rare and undifferentiated cells, 
SCs, are instead responsible for replenishing the pool of differentiated cells while maintaining an 
adequate supply of themselves through the process of self-renewal. SCs can divide 
asymmetrically to produce one daughter cell that is more committed to a specific cell lineage, a 
transit amplifying (TA) cell, and one that retains stemness. SCs have a slower cycling time, on 
the order of one per day, whereas TA cells have a limited life span and self-renewal potential 
while re-populating the differentiated cells of the tissue 
6
. TA cells divide every 12-16 hours, 
surviving for 48 hours and go through approximately 5 rounds of division before being 
exhausted 
7
. Differentiated cells have completely lost the ability to self-renew and succumb to 
apoptosis after their role is absolved. 
The intestine is organized in this hierarchical fashion and its epithelium is renewed every 
five days in humans 
8
.  In this very dynamic process lies a complex collection of epithelial cell 
lineages along with an intricate set of molecular mechanisms to maintain order. The intestine is 
functionally divided into two sections, the SI and the LI. Both are structurally organized in an 
elegant network of invaginations, termed crypts. Villi, present only in the SI, provide a higher 
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surface area to aid in optimal digestion of food and absorption of nutrients. The LI is void of villi 
and is responsible for absorption of water and waste removal. SCs of both the SI and LI are 
located at the crypt base and produce epithelial cells that are committed to three to four different 
cell lineages. These differentiated cells are the absorptive enterocytes, mucus-secreting goblet 
cells and hormone-secreting enteroendocrine cells that will migrate up the crypt wall to form the 
intestinal epithelium (Figure 1, left). A fourth cell, the Paneth cell, is only present in the SI and 
occupies the base of the crypt among the SCs 
9
. 
 
Apoptotic cell 
Colon 
Stem 
Cell 
Transit  
Amplifying  
Cell Goblet 
Enterocyte 
Enteroendocrine 
Colon 
CSC 
Transit  
Amplifying  
Cell 
Normal Colon Adenoma Cancer 
 
Figure 1: Organization of intestinal crypts and their transformation to cancer. Intestinal SCs are located at the 
base of the crypt in normal SI and LI and produce more differentiated cells as they migrate up the sides of the crypt. 
An adenoma will develop in the LI upon deregulation of SC homeostasis. Upon further neoplastic injuries, SCs will 
transform into cancer stem cells (CSCs) with some limited ability to differentiate 
10
. 
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1.1.1 Intestinal SC niche 
In 1978, Schofield observed that hematopoietic cells derived from the spleen have decreased 
proliferative potential when compared to those from bone marrow, the first description of a SC 
niche 
11
. It followed that there may be specialized environments that maintain proliferative 
potential but limit differentiation, the perfect combination for homeostatic regulation of SCs. It 
was not until 2007, thanks to the improvement of lineage tracing strategies, that the SI SC niche 
was fully described in mammals, containing vascular components, fibroblasts and Paneth cells 
providing factors such as Wnt, Bone Morphogenetic Protein (BMP) and Notch 
6
. 
Paneth cells, which are interspersed between SCs and the surrounding subepithelial 
mesenchyme in the SI, express many factors believed to be intricately involved in niche 
maintenance including EGF, Wnt3 and Notch ligands Delta-like ligands Dll1 and Dll4 
12
. 
However, Wnts and EGFs are also produced by sub-epithelial mesenchyme 
13
 in addition to 
BMP inhibitors, not produced by Paneth cells 
14
. Finally, Rspondins are required for maintenance 
of intestinal organoid cultures in vitro, but their in vivo source is yet unknown 
5
. 
While multiple experimental evidences indicate the importance of Paneth cells in the 
intestine 
9, 15
, these studies are limited to the SI, as the LI is void of lysozyme-expressing Paneth 
cells. This raises the question of differential regulation of SCs in the two compartments of the 
intestine. However, Paneth cells in the SI reportedly express CD24 and a similar cell, previously 
described as a non-goblet secretory cell was found to express CD24 in the LI crypt 
9, 16
. This may 
be a cell providing similar signals to LI SCs in the absence of a true Paneth cell, but it has not 
been definitively identified. 
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1.1.2 Intestinal SCs 
Before the discovery of intestinal SCs, a model for repopulation of the intestinal epithelium was 
being formed. The idea that cells flowed from crypts to villi in a “conveyor belt” mechanism was 
first demonstrated by autoradiography 
17-19
. The identity of the crypt base columnar (CBC) cell, 
following the Unitarian Theory that all cells in an intestinal crypt are derived from one cell, was 
not investigated until 1974 
20
. Elementary lineage tracing of radioactive phagosomes indicated 
that differentiated lineages were derived from CBC cells 
21
. Later, chemical mutagenesis allowed 
other groups to visualize ribbons of cells moving from crypt to villous tips with long-lived 
clones, presumably the fully differentiated compartment, and short-lived clones, presumably the 
TA compartment 
22, 23
. Some controversy began with Potten’s identification of a label-retaining 
cell (LRC) at the +4 position in the intestinal crypt 
7, 24
. Label retention suggests mitotic 
quiescence and stemness, however, other groups have since shown that these cells cycle every 
day and their label retention is due to their asymmetric segregation of old (labeled) DNA and 
new (unlabeled) DNA 
7, 25
. This is unlike CBC cells, which segregate their chromosomes 
randomly 
26-28
.  
The identification and regulation of SCs in the intestine has evolved rather rapidly in 
recent years. More sophisticated in vivo lineage tracing studies have identified leucine-rich 
repeat-containing G-protein coupled receptor 5 (LGR5)
+
 SCs in the mouse as cells capable of 
generating all the epithelial cells of the intestine, dividing every day, and forming crypt-like 
structures in vitro 
5, 6
. Their ability to divide every day in vivo and complete 1,000 cell divisions 
in a lifetime allows them to exceed the Hayflick limit in appropriate in vitro settings without 
evidence of transformation or senescence 
5, 29
. In this tightly controlled system, growth factors 
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and three-dimensional matrix support the growth of epithelium with structures resembling that 
found in vivo. 
These studies confirmed and expanded the idea that the Wnt pathway is critical for 
homeostatic crypt formation and maintenance in the intestine 
30
. Interestingly, LGR5, a 
serpentine receptor is a facultative member of the Wnt receptor complex that responds to 
secreted Wnt pathway agonists such as Rspondins 
31-34
. Not only is LGR5 a Wnt receptor, it is 
also a Wnt target, repressed upon inhibition of the pathway 
6
. It is evident that the SCs of the 
intestine are intricately controlled by Wnt signals via their expression of LGR5 and synergistic 
signal transduction. 
 In addition to the LGR5
+
 CBC SC, a population of +4 cells has recently been 
characterized as slow cycling, therefore different from Potten’s fast cycling +4 cell, and able to 
proliferate, expand, self-renew and give rise to all differentiated cells of the intestine 
35
. Further, 
upon ablation of Lgr5
+
 cells, crypt homeostasis seemed unperturbed, owing to Bmi1
+
 cells 
repopulating the epithelium 
36
. Therefore, some have proposed a model in which Lgr5 SCs are 
responsible for homeostatic maintenance of the intestine while Bmi1
+
 cells are responsible for 
injury-induced regeneration 
32
. However, it is important to note that the Bmi1
+
 population of SCs 
was only found in the SI, indicating the lack of a second SC population in the LI if the LGR5 SC 
is lost due to injury or transformation.  
1.1.3 Differentiated cells of the intestine 
The differentiated cells of the intestine work in concert as a specialized ecosystem to carry out 
the functions of the intestine. This specialized layer protects the host from a myriad of insults 
from the harsh contents of the intestinal lumen. In the SI, digestive enzymes work to digest food 
 7 
and absorb nutrients before the LI eliminates indigestible food particles. Four main cell types are 
present in the SI, while one, the Paneth cell is absent from the LI 
21
. 
Enterocytes are by far the most numerous of the intestinal cell types and make up a 
majority of the epithelial lining 
21
. Their cell polarity and structural properties give the intestinal 
epithelium its integrity, while being able to take up and process antigens that penetrate the 
protective mucin layer 
37
.  
Goblet cells produce a variety of high molecular weight glycoproteins, called mucins 
37-
39
. Mucins provide a viscous extracellular layer for defense and defects in this mucous layer can 
increase bacterial adhesion, permeability, inflammation and cancer 
40
. Most importantly, the 
mucin layer functions to allow adhesion of resident microbiota while preventing the attachment 
of pathogenic microorganisms 
39
. 
Enteroendocrine cells export peptide hormones from secretory granules 
37, 41, 42
. They act 
as luminal surveyors, responding at their basolateral side to nutrient sensing at the apical surface 
43
. This results in the control of physiological functions such as glycemia, exocrine pancreatic 
secretion, growth and repair of the gut epithelium, motility of the gut wall and gastric emptying 
44, 45
. It has been reported that the Notch-Hes axis (discussed below) is pivotal in enteroendocrine 
cell differentiation, with Hes1 antagonizing expression of enteroendocrine cell-specific 
neurogenin3 and blocking differentiation to that lineage 
44, 46
.  
Lastly, Paneth cells secrete antimicrobial cryptdins or defensins, digestive enzymes and 
growth factors 
37
. Unlike the other three cell types, these cells migrate down to the base of the 
crypt, rather than in an upward direction, becoming part of the SI SC niche. Even though 
separated spatially from goblet cells, Paneth cells also play a role in enteric defense, producing 
antimicrobial peptides 
42
. Wnt and Notch signaling work in concert to regulate Paneth cell 
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differentiation 
47, 48
. With such important roles, it is interesting that the LI can avoid injury 
without this cell population, however, it may explain why it is more susceptible to cancer 
formation, especially since cancer is likely to arise from inflammation-plagued epithelium. 
1.2 SIGNALING PATHWAYS IN INTESTINAL HOMEOSTASIS 
The two main signaling pathways responsible for homeostasis in the intestine, the Wnt pathway 
and the Notch pathway have extensive cross-talk with their involvement in cell fate decisions, 
proliferation, differentiation and tumorigenesis 
48, 49
. Thus far, a majority of studies elucidating 
these pathways in the intestine have not made clear distinctions between the SI and LI. 
1.2.1 Wnt Pathway 
Wnt signaling is one of the driving forces of crypt formation and maintenance in the colon 
30
. In 
the absence of Wnt signals, a destruction complex sequesters beta-catenin in the cytoplasm with 
axin, adenomatous polyposis coli (APC) and glycogen synthase kinase 3 (GSK3) beta 
50, 51
. This 
complex marks beta-catenin for degradation and leads to a decrease in Wnt targeted 
transcription. When Wnt proteins bind Frizzled/LRP receptors, the canonical Wnt pathway 
ensues. This involves the disruption of the destruction complex and allows beta-catenin to enter 
the nucleus and in concert with transcription factor 4 (TCF4), trigger transcription of Wnt targets 
52, 53
 (Figure 2). Two of the known Wnt targets are cyclin D1 and c-myc oncogene, both 
overexpressed in colon cancer 
54, 55
. 
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Figure 2: The Wnt Pathway. In the absence of Wnt signals (left), the APC destruction complex leads to 
the degradation of beta-catenin. When Wnt signals bind to Wnt receptors or APC is mutated (right), disruption of 
the complex allows beta-catenin to move into the nucleus for transcriptional regulation of Wnt genes in concert with 
TFC transcription factors. 
 
 
The dysregulation of the Wnt pathway and its role in self-renewal as well as differentiation have 
been shown to be required for the development of cancer 
30
. Mutations in APC have been 
implicated in both the sporadic and inherited forms of colorectal cancer, causing an accumulation 
of beta-catenin in the nucleus and enhanced Wnt signaling 
56-60
. Therefore, if aberrantly active, 
the Wnt pathway could result in an expanded progenitor population and colon cancer (Figure 1). 
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1.2.2 Notch Pathway 
The Notch pathway determines cell fate decisions in the intestinal crypt. Upon binding of a 
Notch ligand on one cell to a Notch receptor on another cell, gamma-secretase cleaves the 
intracellular tail of the Notch receptor, the Notch Intracellular Domain (NICD), which 
translocates to the nucleus for transcriptional signaling
61
. The most well-known targets of Notch 
are the hairy/enhancer of split (HES) family of transcription factors, principally HES1 for its 
involvement in the intestine 
46, 62
. Notch receptors 1 and 2 are expressed on SCs and TA cells in 
intestinal crypts and mediate the expression of HES1, blocking transcription of atonal homolog 1 
(ATOH1) and differentiation 
48, 63, 64
. DLL1 and DLL4 are ligands for these receptors and can be 
found on the surface of Paneth cells in the SI 
65
. While activation of the Notch pathway represses 
secretory cell differentiation 
66
, inhibition of Notch leads to activation of ATOH1 promoting 
goblet cell differentiation in intestinal crypts and adenomas 
48, 67
 (Figure 3). Again, it is important 
to note that a majority of these studies have been carried out in the SI. Therefore, it has largely 
been assumed that the same holds true for the LI. 
 
Muc2 
Hes1 
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NICD 
GS 
Goblet Cell Progenitor Cell 
NOTCH 
NICD 
X 
ATOH1 ATOH1 
X 
 
Figure 3: Notch signaling in intestinal cells. Lateral inhibition via expression of Notch receptor on one 
cell and Notch ligand on a neighboring cell. GS = gamma secretase. 
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The manipulation of the Notch pathway via drug intervention is an attractive approach to 
target CSCs. Gamma-secretase inhibitors have been shown to reduce cancer growth, inhibit CSC 
self-renewal and increase differentiation to goblet cells 
67
. Similar results were found with small 
molecule and RNA knockdown studies, showing that the inhibition of Notch leads to increased 
apoptosis, decreased self-renewal and increased secretory cell lineage differentiation of CSCs in 
colon cancer 
66
.  In yet another study, inhibition of DLL4 inhibited the expression of Notch 
targets and reduced tumor initiating cell frequency 
68
. These targeted therapies may enhance the 
efficacy of chemotherapeutic drugs when used in sequence or combination 
69
. However, these 
are mechanisms shared with normal intestinal SCs and may lead to toxicity. 
1.3 SMALL INTESTINE VERSUS LARGE INTESTINE 
Even though the SI and LI vary greatly in their function and structure, comprehensive studies 
have not been done to explain the origin of these differences and their relation to disease. An 
accumulation of evidence of their differences may prove to be important to intestinal disease 
susceptibility. 
1.3.1 Cycling time 
In mouse intestinal lineage tracing assays, LI SCs seem to cycle slower than their SI SC 
counterparts as evidenced by LacZ cells remaining restricted to the crypt base after 5 days, when 
in the SI, full ribbons of cells were observed 
6
. Full ribbons of LacZ positive cells did increase in 
later days, indicating the ability of LI SCs to self-renew long-term. The difference in rate of 
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epithelial turnover between the SI and LI may be an indication of differential intrinsic responses 
to environmental cues. 
1.3.2 Resistance differences 
SCs are charged with the task of maintaining genomic integrity and tissue homeostasis. 
Therefore, their resistance to damage must be higher than more differentiated cells. This is a 
distinguishing factor between SCs of the intestine. The quiescent +4 cell in the SI crypt is 
sensitive to ionizing radiation, while its rapid cycling counterpart, the LGR5
+
 CBC SC, is more 
resistant 
6, 7, 70
. The surviving LGR5
+ 
SCs, presumably with better DNA repair mechanisms, can 
then repopulate the SI after injury. Thus, even if +4 Bmi1
+
 cells serve as a reserve SC in the SI, 
but are absent from the LI, LGR5
+
 SCs are still able to rescue the tissue. Additionally, LI SCs 
seems to be more resistant than their SI SC counterpart, possibly contributing to therapy 
resistance and higher occurrence of LI cancer over SI cancer 
71
. 
Prior to well-defined lineage tracing and specific identification of +4 (Bmi1
+
) and CBC 
(LGR5
+
) SCs in the intestine, apoptotic differences in SC positions were observed between SI 
and LI crypts. Spontaneous and irradiation-induced apoptosis were higher in the SI compared to 
the LI and were maximal at position 4. In the LI, apoptosis was not confined to the crypt base or 
the +4 position, but was distributed along the length of the crypt 
72
. Similarly, the apoptotic and 
mitotic index of the LI are 50-60% and 45-70% of the values for the SI, respectively 
73
. This may 
be due in part to differential expression of bcl-2, an inhibitor of apoptosis. While bcl-2 is 
expressed in CBC cells of the LI, it is absent from SI crypts. Therefore, when apoptosis was 
observed in bcl-2 null mice, it rose significantly at the base of LI crypts, while remaining 
unchanged in SI crypts 
72
. It has also been reported that LI SCs have lower expression of p53, a 
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tumor suppressor and DNA damage responder 
74, 75
. Since apoptosis is a mechanism by which 
damaged cells are removed from the epithelium, a decrease in apoptosis in the LI may predispose 
its SCs to propagate damaged cells, which may lead to transformation. Once transformation 
occurs, the newly firmed CSCs likely have inherited the resistance of the cells of origin. 
1.3.3 Wnt pathway differences 
As mentioned above, the Wnt pathway is the most perturbed pathway in LI cancer and is 
responsible for homeostasis in the normal intestine. It is generally accepted that upon Wnt 
activation, beta-catenin translocates to the nucleus where is binds to TCF factors (namely TCF4), 
entering into a transactivation complex to enhance the expression of downstream targets of Wnt. 
As mentioned before, most of these studies have been carried out in the SI and it was not until 
the expression of TCF4 (encoded by Tcf7l2) was assessed along the entire intestine, that its 
expression was seen to be limited to the SI. A KO in this gene had no affect on the phenotype of 
LI crypts, but the SI lacked proliferative compartments completely 
30
. The expression of Tcf7l1 
(TCF3) is thought to have functional redundancy in the intestine and may be the mechanism used 
to transmit Wnt signals in the LI 
30, 76
. TCF3 has an unconventional interaction with beta-catenin. 
When beta-catenin binds to TCF3, it reduces TCF3 chromatin occupancy and causes degradation 
of TCF3, thus releasing its repressor role, and allowing for the transduction of Wnt signaling 
77
. 
These interactions demonstrate a delicately controlled system of Wnt signals in the LI. 
Furthermore, there is controversy as to the function of TCF4 as a tumor suppressor or oncogene 
78
. In any case, differences between human and mouse as well as SI and LI must be investigated 
further to truly understand the involvement of TCF factors in small and large intestinal 
homeostasis and carcinogenesis. 
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1.4 NORMAL STEM CELLS VERSUS CANCER STEM CELLS 
Since the hallmarks of SCs are their ability to self-renew and differentiate, investigators were 
prompted to explore the similarities and differences that exist between normal SC maintenance 
of tissues and organs and the uncontrolled proliferation of cancer 
79
.  Abnormal cellular behavior 
in this tightly controlled system can occur via genetic alterations such as tumor suppressor loss 
or gene destabilization that result in incremental neoplastic gains and disruption of the 
homeostatic system 
80
. In essence, tumors can be viewed as small aberrant organs containing a 
hierarchy of progenitor cells and differentiated cells (Figure 1). Albeit dysfunctional in the 
bodily view, they maintain their own abnormal proliferation and survival mechanisms 
81
. If 
tumors are indeed aberrant organs, then there is a program by which the system is controlled, 
however loosely it might be. Therefore, in the cellular hierarchy of a tumor, there is a 
differentiation mechanism from CSC to tumor progenitor cell to mature cancer cell that ends in 
apoptosis and turnover 
82
.  
1.4.1 Intestinal SCs as the cell of origin of cancer 
The CSC theory presents a situation where a cancerous cell, formed from mutations in a normal 
SC, inherits the characteristics of the cell of origin. This concept was nicely demonstrated after 
deletion of APC in LGR5
+
 intestinal SCs, which led to rapidly growing adenomas, suggesting 
that normal SCs are the cell of origin of intestinal cancer
4
. Furthermore, murine adenomas 
revealed continual LGR5
+
 SC activity, providing functional evidence of a SC population in these 
pre-cancerous intestinal lesions 
83
. Alternatively, the +4 Bmi1
+
 SCs were also able to generate 
adenomas upon the induction of a stable form of beta-catenin, similar to the LGR5 CBC SC. The 
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protective mechanisms meant to preserve the SC pool become part of the CSC repertoire of 
repair and resistance. These studies provide important evidence of the relation between normal 
and cancer SCs. 
To strengthen the relation between normal and cancer SCs, an intestinal SC signature was 
found on colon CSCs displaying robust tumor-initiating capacity and long-term self-renewal 
potential that also correlated with disease relapse 
84
. This intestinal SC signature was validated in 
situ using a human colorectal gene expression database looking at colorectal adenocarcenomas 
85
. The similarities found between normal LI SCs and colon CSCs support the hypothesis that 
transformative events in LI SCs produce colon CSCs capable of fueling cancer growth and 
assumes differences between SI SCs and LI SCs contribute to the higher frequency of LI cancer. 
1.4.2 Intrinsic versus extrinsic factors 
In any cellular environment there are extrinsic factors, including matrix, neighboring cells and 
secreted factors that can alter a cell’s behavior, telling it to proliferate, differentiate, move or die. 
There are also intrinsic factors that determine the cellular response to these environmental cues. 
The same cues could lead to differential responses in two differently programmed cells. In LI 
cancer, intrinsic resistance in cancer cells determines response to treatment 
86
. Colitis-associated 
carcinogenesis may be triggered by an intrinsic defect in Maltripase, an important component of 
tight junctions, leading to a compromised permeability barrier 
87
. Loss of APC and activation of 
KRAS, followed by nuclear beta-catenin accumulation, as the first steps from adenoma to 
carcinoma sequence, are considered intrinsic alterations causing an effect in cellular behavior 
88
. 
In normal intestinal crypts, it is Wnt, Notch and BMP signaling that determines SC proliferation 
and differentiation, and upon transformation, an altered maintenance of colon CSCs 
89, 90
. 
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Alternatively, normal intestinal crypts and their resident SCs may be extrinsically 
maintained. If SCs divide symmetrically 
91
, it may be their surroundings, such as neighboring 
cells, that determine their fate instead of intrinsic mechanisms laid out at the birth of a cell 
92
. 
Extrinsically, the leading edge of a growing cancer is inundated with signals from the 
microenvironment. Myofibroblasts produce extracellular matrix, secrete cytokines and growth 
factors that signal for proliferation and invasion of tumor cells 
93
. Furthermore, HGF, often found 
in the tumor microenvironment, enhances tumor growth and invasion via Wnt/beta-catenin 
signaling, an example of the intrinsic working with the extrinsic for survival of the fittest cancer 
cell 
94, 95
. Other extrinsic factors can be derived from pathogens or cellular damage, but it is the 
intrinsic cell programming for molecules such as receptor for advanced glycation end products 
(Rage) that determines the response to such signals 
96
. Therefore, it is a synergistic battleground 
of intrinsic versus extrinsic signaling that ultimately determines cellular response. Either set of 
signals or a combination of the two can determine differences between two cell populations. 
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2.0  EXPANSION OF NORMAL HUMAN SMALL AND LARGE INTESTINAL 
EPITHELIAL CELLS 
Few methods allow the successful expansion of undifferentiated SCs of the human intestine. To 
overcome this limitation, we used feeder cells as a stromal layer to provide cell-cell interactions 
and promote epithelial cell growth 
97
. Our lab has previously used this system to expand CSCs 
from human metastatic colon cancer 
98
. Here, we isolated human fetal SI and LI cells from 
primary tissue and plated bulk intestinal cells on the feeder layer, allowing colonies to form from 
the SC population. In this approach, only the cells with SC characteristics such as colony-
formation and self-renewal propagate. Therefore, there is no bias in identification of SCs via 
markers, only identification and characterization of cells with SC properties. Most importantly, 
we compared SI and LI cells isolated from the same donor tissue, minimizing potential 
discrepancies due to genetic variability. 
2.1 REQUIRED CULTURE CONDITIONS AND INITIAL OBSERVATIONS 
2.1.1 Intestinal epithelial cell expansion required the addition of R-Spondin 2 
Human fetal SI and LI cells from primary tissue were isolated and plated on the feeder layer as 
was done with the human metastatic colon cancer 
98
. However, the plating efficiency was very 
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low with cells surviving only about a week in culture, unable to be passaged. The Wnt pathway 
has previously been shown to be integral to the growth of intestinal cells in vitro 
5
. We found that 
maintenance of normal human intestinal cells required the addition of R-spondin 2, a Wnt 
agonist (Figure 2). Within one week after plating, intestinal cells formed visible colonies among 
the feeder cells that were sustainable up to ten passages. 
2.1.2 Small and large intestinal epithelial cells differ in morphology 
There are dramatic differences in the SI and LI architecture in vivo (Figure 4A). While both the 
SI and LI have invaginations called crypts, only the SI has protrusions called villi. This structure 
is related to function. The structure of the SI lends to absorption and digestion of food. The 
structure of the LI allows for the absorption of vitamins and water as well as removal of waste 
from the body. When the colonies began to form in vitro, differences between SI and LI colony 
density, cell growth, size and shape were observed (Figure 4B). The SI cells formed more 
dispersed colonies with cells of various shapes and sizes while the LI cells formed more compact 
colonies with cells of homogeneous shape and size. 
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Figure 4: Primary human intestinal cells expand on the feeder layer. (A) Hematoxylin and eosin 
paraffin sections of normal fetal SI (left) and LI (right). (B) SI (left) and LI (right) SCs expanding on the feeder 
layer in vitro. Scale bar = 100μm. 
 
2.1.3 Expanded intestinal cells are epithelial 
Flow cytometry analysis revealed that even though bulk intestinal cells were plated in vitro, 
including blood, muscle and mesenchymal cells, expansion of the cells increased the proportion 
of epithelial cells, as marked by Epithelial Cell Adhesion Molecule (EpCAM), from 21.6 and 
34.3% to 92.3 and 92.4% in primary SI and LI respectively (Figure 5A & B), indicating the 
feeder cells provided an environment that selects for and allows the expansion of intestinal 
epithelial cells.  
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Figure 5: Cells expanded on feeder layer are EpCAM+. (A) Normal human SI and LI cells freshly 
isolated from tissue and analyzed by flow cytometry for EpCAM, excluding blood cells (EpCAM
+
CD45
-
CD235a
-
). 
(B) Normal SI and LI epithelial cells expanded in vitro retain EpCAM marker, excluding feeder layer 
(HLA
+
EpCAM
+
). 
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2.2 EXPANDED INTESTINAL CELLS ARE NOT TRANSFORMED 
2.2.1 Expanded intestinal cells do not form tumors in mice 
Since the Wnt pathway is also known to play a role in cancer 
99
 and we used a Wnt agonist to 
propagate them, we wanted to ensure that the cells were not transformed. Expanded intestinal 
cells that had been treated with R-Spondin 2 were injected into the subcutaneous space of 
immunocompromised, Rag-2
-/-
/c-/-, mice. These normal cells failed to form tumors in every 
case. As a control, human colon CSCs (Tu22 from Odoux 
98
) were also injected and formed 
xenograft tumors in every case (Table 2). This is an indication that the normal intestinal cells 
expanded in the feeder layer system are not transformed. 
 
Table 2: Normal intestinal SCs did not form tumors in vivo 
Cell Type Frequency of Tumor Formation
Colon CSC 5/5
SI SC 0/5
LI SC 0/6  
2.3 DISCUSSION 
While human CSCs from primary tissue can be expanded on our feeder layer culture system 
without additional exogenous growth factors, the same system appeared futile for the expansion 
of normal human intestinal cells. However, understanding the importance of the Wnt pathway in 
intestinal crypt maintenance, the addition of R-Spondin 2 greatly enhanced the plating efficiency. 
The initial observations of growth differences between SI and LI cells prompted us to investigate 
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the possibility that the SI and LI are propagated from two different SC populations. To begin 
these studies, it was imperative to first identify the type of cells expanding in our system from 
the bulk primary cells. EpCAM was first discovered as an adhesion molecule, but has since been 
found to play a role in cell cycle and proliferation 
100
. The enrichment of EpCAM
+
 cells in both 
SI and LI cultures validated that these cells were in fact epithelial in nature and could be 
separately characterized from the feeder layer using this marker. EpCAM has long been found to 
be overexpressed on cancer cells and cancer-initiating cells, but more recently, its expression and 
role has been investigated in the context of normal SCs 
101-103
. This was the first indication that 
these cells may be of SC nature.  
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3.0  CHARACTERIZATION OF EXPANDED INTESTINAL EPITHELIAL CELLS 
Many studies of SCs focus on cell surface markers as a way of identification. This identification 
is often linked to SC properties within a specific cell population. Therefore, it was imperative to 
identify cell surface markers present on the expanded intestinal epithelial cells to further 
characterize them as SCs. A panel of markers was selected for their previous identification in SC 
studies of various tissues. Each expanded intestinal cell sample was subjected to panel analysis 
by flow cytometry. While there were some variations within the two groups most likely due to 
genetic variation, many similar and repeatedly disparate patterns emerged between the expanded 
SI and LI cells. These markers were subsequently used in limiting dilution analysis (LDA) 
studies to test their role in self-renewal and colony formation. Furthermore, quantitative flow 
cytometry was used to demonstrate the dramatic growth rate differences between the two SC 
populations. Through these studies, it became apparent that there are intrinsic differences 
between SI and LI SCs that warrant further investigation.  
3.1 CELL SURFACE MARKER PROFILE 
Primary and expanded SI and LI epithelial cells (13 SI and 8 LI) were screened against 16 
antibodies. The marker profile gave rise to many patterns while also showing the effect of 
genetic variation between samples. Three matched SI and LI are shown in Table 3 in comparison 
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to freshly isolated primary cells. While many of the matched samples did share markers within 
SI and LI groups (ex. CD44, CD49b), some were variable (ex. CD227, CD13). When comparing 
primary cells to expanded cells, some apparent selection has occurred (ex. CD166, CD133.1, 
CD66c, CD49f), indicating enrichment for a particular population of cells.  
 
 
Table 3: Phenotypic profile of primary and expanded intestinal cells.  
Primary and expanded SI and LI cells were screened against 16 antibodies. For primary cells, blood cells 
were eliminated by CD235 and CD45, then EpCAM was used to gate on epithelial cells prior to marker profiling. 
For expanded cells, HLA was first used to distinguish the human cells from the rat feeder layer, then EpCAM was 
used to gate on epithelial cells prior to marker profiling. One representative primary sample is presented here for 
primary cells and three matched SI and LI samples for expanded cells. +/- indicates more cells are expressing the 
marker than are not expressing the marker, -/+ indicates more cells are not expressing the marker than are expressing 
the marker, low+ indicates that the expression of that marker was low. 
Marker Primary SI 
Expanded SI 
1 
Expanded SI 
2 
Expanded SI 
3 
CD9 + + + + 
CD13  + +  +/- + 
CD24  - low+ low+ low+ 
CD26  +/- + + + 
CD29  +/- low+ + low+ 
CD34  - - - - 
CD44  - - - - 
CD49b  + + + + 
CD49f  - + + + 
CD54  - - - - 
CD66c  -/+  +/-  +/- + 
CD90  - - - - 
CD133.1  -/+  -/+  +/-  -/+ 
CD133.2  -/+  +/-  +/-  -/+ 
CD166  - + + + 
CD227  -  -/+  -/+ - 
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Marker Primary LI 
Expanded LI 
1 
Expanded LI 
2 
Expanded LI 
3 
CD9 + +  - low+ 
CD13  +/-  -/+  +/-  +/- 
CD24  -  + + low+ 
CD26  +/- +  +  +/- 
CD29  -/+ +  + + 
CD34  - -  -  - 
CD44  - -  -  - 
CD49b  + +  +  + 
CD49f low+ + low+  + 
CD54  -  +/-  -/+  - 
CD66c  +/-  -/+  -/+  -/+ 
CD90  - -  -  - 
CD133.1  -/+ +  +  + 
CD133.2  -/+ +  +  + 
CD166  - +  +  + 
CD227  -/+ +  -  - 
 
3.1.1 Small and large intestinal cells share many cell surface markers, including markers 
of SCs 
Analysis by flow cytometry indicated that intestinal cells co-cultured with the feeder layer 
expressed several putative SC markers. CD133.1 (CD133 AC133) has long been accepted as a 
marker of colon CSCs 
104
. While primary SI and LI cells contained less than 1% CD133.1
+
 cells, 
the expanded cells comprised 69.4 and 73.8% CD133.1
+
 cells for the SI and LI, respectively 
(Figure 6A). Other putative SC markers showed similar expression profiles, including CD166 105, 
CD24 
106
 and CD49f 
107
 (Figure 6B). 
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Figure 6: Culture system enriches for intestinal SCs. (A) Flow cytometric analyses of EpCAM+ primary 
SI and LI cells indicate <1% population of CD133.1
+
 cells (left), as seen in contour plots. Analysis of EpCAM
+
 SI 
and LI cells expanded on the feeder layer indicates an enrichment of CD133.1+ population (right), as seen in 
contour plots. (B) Expanded SI and LI cells express other putative SC surface markers. Histograms represent 
unstained control (blue) and stained cells (red). 
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3.1.2 Normal intestinal SCs versus colon CSCs 
The same SC markers that were expressed on both SI and LI SCs (Figure 6A & B) were also 
expressed by CSCs derived from human metastatic colon cancer (Figure 7A). Notably, CD44, a 
cell surface glycoprotein involved in cell-cell interactions and thought to be related to distant 
metastasis of colorectal cancer (CRC) 
108
, was consistently negative on both normal SI and LI 
SCs but positive on colon CSCs grown under the same conditions (Figure 7B). This indicates 
that CD44 may play a key role in cancer as suggested by other groups that targeted CD44 with 
shRNA, reducing cell growth and invasion and increasing apoptosis 
109
. 
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Figure 7: Shared and disparate expression of SC markers between normal intestinal SCs and colon 
CSCs: (A) Flow cytometric analysis indicating expression of CD133.1 (contour plot), CD166, CD24 and CD49f 
(histograms) on previously characterized colon CSCs (Tu22) 
98
. (B) CD44 is consistently negative on normal 
intestinal SCs and positive on colon CSCs. Histograms represent unstained control (blue) and stained cells (red). 
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3.1.3 Differential expression of specific cell surface markers indicates fundamental 
differences between SI and LI SCs 
Flow cytometry analyses of CD133.1, CD13, and CD66c expression revealed reproducible 
differences between SI and LI SCs expanded in vitro (Figure 8A & B). CD133.1 expression was 
higher in LI cells compared to a low, broad expression in SI cells. We found an opposite 
expression profile using CD13, an aminopeptidase whose expression decreases from ascending 
to descending colon and possibly plays a role in the different cancer incident rates of these two 
segments 
110
. CD66c, also known as carcinoembryonic antigen cell adhesion molecule 6 
(CEACAM6), was notably different between the SI and LI SCs, where 79.8% of the expanded SI 
cells expressed high levels of CD66c and 89.4% of the expanded LI cells expressed CD66c at a 
low level (Figure 8A). Three paired SI and LI samples showed reproducible expression 
differences of CD133.1, CD13 and CD66c using flow cytometry staining index as the output 
(Figure 8B). 
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Figure 8: Small and large intestinal SCs differ by cell surface marker expression. (A) Flow cytometry 
shows differential expression between paired intestinal SCs of CD133.1, CD13 and CD66c as seen in histograms 
with expression of CD66c
lo
 comprising 20.2% in SI and 89.4% in LI, and CD66c
hi
 comprising 79.8% in SI and 
10.6% in LI. Histograms represent unstained control (blue) and stained cells (red). All markers were PE-labeled.  
The same control was used for SI CD13 and CD66 as well as LI CD133 and CD13 because they were analyzed on 
the same day. (B) Corresponding staining index of paired samples (staining index = D/W, where D is the distance 
between the positive and negative populations and W is two standard deviations of the negative population). 
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3.2 SELF-RENEWAL AND GROWTH RATE 
3.2.1 CD66c expression distinguishes SI from LI SCs 
 LDA was used to assess the clonogenic potential of SI and LI SC populations. LDA is a 
quantitative measurement that can determine the colony-forming frequency of a specific cell 
population. Increased colony-forming frequency correlates with stem cell activity 
111
. Using 
Fluorescence Activated Cell Sorting (FACS), we sorted three different tissue-matched cultures of 
SI and LI SCs in limiting dilution based on HLA
+
/EpCAM
+
 expression. Four weeks after plating, 
we calculated the colony-forming unit (CFU) frequency of the cells by linear regression 
112
. The 
frequency of the EpCAM
+
 colony-forming SI and LI SCs was similar, and ranged from 1/10 to 
1/106 (Table 4).  
 
 
Table 4: CFU Frequency of HLA+/EpCAM+ cells. LDA was carried out on expanded HLA+/EpCAM+ SI 
and LI SCs. CFU frequency ± SE (L-Calc) for SI and LI SC cultures indicated a high potential for colony formation 
among this cell population. 
LDA CFU Freq.
SE Range in CFU 
Frequency
SI 1 1/60 1/15-1/8
SI 2 1/10 1/17-1/9
SI 3 1/25 1/16-1/8
LI 1 1/22 1/32-1/18
LI 2 1/106 1/279-1/160
LI 3 1/38 1/103-1/58  
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Next, we sorted the same set of cultures in limiting dilution based on differing CD66c expression 
levels. Interestingly, SI SCs that expressed low levels of CD66c had a higher CFU frequency 
than CD66c
hi
 cells, while LDA results for LI cells were reversed (Table 5). This reveals a 
fundamental difference between SCs of the SI and LI. 
 
 
Table 5: CD66c distinguishes SI from LI SCs. LDA was carried out on expanded HLA+/EpCAM+ 
CD66c
hi
 versus CD66c
lo
 SI and LI SCs. CFU frequency ± SE (L-Calc) for SI SC cultures indicated the CD66
lo
 
fraction is enriched with colony forming cells while the LI SC cultures show the opposite result with the CD66
hi
 
fraction enriched with colony forming cells. 
LDA Population CFU Freq.
SE Range in CFU 
Frequency
CD66c lo 1/11 1/15-1/8
CD66c hi 1/78 1/103-1/58
CD66c lo 1/12 1/17-1/9
CD66c hi 1/25 1/30-1/18
CD66c lo 1/11 1/16-1/8
CD66c hi 1/34 1/45-1/25
CD66c lo 1/24 1/32-1/18
CD66c hi 1/9 1/13-1/7
CD66c lo 1/211 1/279-1/160
CD66c hi 1/15 1/20-1/11
CD66c lo 1/77 1/103-1/58
CD66c hi 1/13 1/18-1/10
LI 2
LI 3
SI 1
SI 2
SI 3
LI 1
 
 
3.2.2 LI SCs have a higher growth rate than SI SCs 
Next, flow cytometry was used to quantitatively measure intestinal SC proliferation in vitro. We 
plated SI and LI SCs from three paired samples in triplicate with a defined number of cells (day 
0) and counted the number of EpCAM
+
 cells on days 1, 4, 8 and 11. For all three paired samples, 
LI SCs showed significantly greater cell numbers than the SI SCs at each time point (Figure 9). 
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This is in contrast to previous in vivo results, indicating that the mouse SI turns over at a higher 
rate than the LI 
6
. This result demonstrates one important difference between mouse and human 
intestinal homeostasis. 
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Figure 9: LI SCs have a higher growth rate than SI SCs. Quantitative flow cytometry was used to count 
the number of EpCAM
+ 
cells at 1,4,8 and 11 days after plating 93,750 cells/well in triplicate on day 0. One 
representative pair of two examined is shown here. 
3.3 DISCUSSION 
This set of experiments not only characterized the normal SI and LI epithelial cells as SCs, but 
also began to decipher key differences between the two cell populations. The broad panel of 
markers showed that the culture system selected for a defined population of EpCAM
+
 epithelial 
cells expanded from primary bulk cells and that the cells were more homogenous than cells from 
primary tissue. This can be seen in the movement from a +/- or -/+ in Table 3 to a + or – 
expression pattern for most markers. This identifies the strength of the culture system, 
demonstrating that it selects for a homogenous population having the ability to form colonies and 
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eliminating those that cannot. The expression of CD166, CD24 and CD49f not only further 
verify their SC identification, but also the similarities of SI and LI SCs to one another.  
In contrast, the expression of CD133.1, CD13 and CD66c began to identify differences 
between SI and LI SCs. The enrichment of CD133.1
+
 populations laid the groundwork for future 
SC studies and their relation to cancer since this marker has been studied extensively in the CSC 
field 
102, 104, 113
. This is of particular interest since CD133.1 is reproducibly more highly 
expressed in the LI SCs than the SI SCs (Figure 8B). Considering its relation with CSCs, a 
higher expression of CD133.1 on LI SCs may indicate a predisposition to neoplastic 
transformation compared to SI SCs.  
While the ascending and descending segments of the LI were not separated here, there 
have been some studies indicating differences in gene expression. CD13 was expressed at a 
higher degree in the ascending colon versus the descending colon 
110
. If this pattern continues 
proximal, into the SI, this can explain the higher expression found in the SI SCs compared to the 
LI SCs. 
Furthermore, we specifically compared normal intestinal SCs with colon CSCs and found 
very similar SC marker expression among all three cell types. This indicates that normal 
intestinal SCs may be the cell of origin for cancer. This was more directly demonstrated in mice 
where APC was specifically deleted in LGR5+ ISCs, leading to rapidly growing adenomas. This 
indicated that SC specific loss of APC could be one of the initial hits on the way to cancer 
formation 
4
. Importantly, while both normal SI and LI SCs shared many markers with colon 
CSCs, they lacked expression of CD44 (Figure 7). Due to its role in distant metastasis of 
colorectal cancer 
108
, lack of CD44 expression on normal cells provided another indication that 
these cells were not transformed, in addition to their failure to form tumors in vivo (Table 2).  
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An unexpected finding was that the disparity in expression of CD66c identified opposing 
populations of SI and LI SCs capable of forming colonies (Table 5). We used the difference in 
expression, and sorted the hi- and low-expressing populations, finding that the minority 
population in each case (10.6% of CD66c
hi
 for LI SCs and 20.2% of CD66c
lo
 for SI SCs) was the 
population that held the most self-renewal potential. In addition, although most markers are 
homogenously expressed on the expanded cells, this marker alone identifies a subset that most 
likely separates the progenitor cells from the true SCs in this system. A recent study showed that 
high expression of CD66c was associated with colon CSCs and silencing CD66c blocked tumor 
growth 
114
. The LDA result was reproducible for three paired samples and is likely a conserved 
and important phenomenon. Like CD133.1, high CD66c expression in LI SCs may indicate why 
these SCs are more susceptible to transformation than their SI counterparts expressing low levels 
of CD66c.  
Even though it seems that EpCAM
+
 SI and LI SCs have nearly equal colony formation 
ability, the expanded human LI SCs have a significantly higher growth rate when compared to SI 
SCs (Figure 9). This is in contrast to previous in vivo results, indicating that the mouse SI turns 
over at a higher rate than the LI 
6
. This result may identify important differences between mouse 
and human intestinal homeostasis. Lineage tracing in mice indicated that while at 5 days, entire 
crypts were lineage marked from the LGR5
+
 SCs in the SI, lineage marking was still restricted to 
the crypt bottom in the LI, indicating more quiescence in the LI compared to the SI 
6
. Therefore, 
in the mouse, SI SCs seem to divide more readily than the LI SCs, an opposing result to our 
human intestinal SC data. Interestingly, the APC/min mouse, with a heterozygous loss for APC, 
develops ten times more SI tumors than LI tumors, whereas humans develop twenty times more 
LI cancer than SI cancer 
115, 116
 (Table 1). The discrepancy in location of tumors between mouse 
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and human seems to be related to the difference in proliferation rates. A higher proliferation rate 
in the mouse SI may be related to higher incidence of SI cancer, whereas a higher proliferation 
rate in the human LI may be related to a higher incidence of LI cancer. Entire studies have been 
performed using tumors generated in the mouse SI, a fact that is generally only disclosed in the 
methods section 
117
. If the origin of mouse intestinal cancer, the SI SC, is different from the LI 
SC, their mechanisms of tumorigenicity and responses to therapy may differ. Only recently have 
mouse models of colon cancer emerged. Even these rely on inflammation induction of colon 
cancer, which has a very different progression from normal epithelium to cancer 
118
. The 
differences between SI and LI SCs may change the way researchers use mouse models and relate 
them to human colon cancer.  
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4.0  MOLECULAR DIFFERENCES BETWEEN SMALL AND LARGE INTESTINAL 
STEM CELLS 
While important for identification and live cell sorting, cell surface marker expression gives a 
limited view of the inner workings of SCs. Complex intracellular mechanisms give the cells their 
identity and function. Interestingly, researchers agree that normal SCs and CSCs share many 
characteristics. They both have the ability to self renew and differentiate into the multiple cell 
lineages of their parent organ while having a higher clonogenicity than other, more differentiated 
cells
90
.  
As discussed above, Wnt signaling is a driving force of crypt formation and maintenance 
of the intestine 
30
 via its many targets, including LGR5, but its disruption is also what is 
responsible for the transformation of human intestinal epithelial cells 
119
. Likewise, the Notch 
pathway is not only involved in the maintenance of progenitor cells of the intestine 
48
, but also in 
the cell fate decisions 
67
. Changes in these gatekeeper pathways in SI and LI would have a great 
impact on their regulation and susceptibility to disease.  
To better understand the molecular characteristics and functional aspects of SI and LI 
SCs, they were subjected to gene array analysis. For a robust comparison, the samples consisted 
of four matched SI and LI SC samples and two sets that were unmatched. 
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4.1 DIFFERENTIAL GENE EXPRESSION PATTERNS INDICATE SEPARATE 
MOLECULAR SIGNATURES IN SMALL AND LARGE INTESTINAL SCS 
Gene array analysis provided a glimpse into the molecular signature of the SI and LI SCs. Of the 
thousands of significantly different transcripts, 1118 had a fold change greater than 1.5. The two 
different cell types clustered separately using unsupervised hierarchical clustering methods 
where the distances are defined linearly (left axis, Figure 10). This reinforces the inherent 
similarities within each group, while still demonstrating clear differences between SI and LI SCs. 
It is important to note that feeder cells were also subjected to gene array analysis to ensure they 
were profoundly different from the SI and LI SCs. Indeed, in both cases, most of the transcripts 
are expressed at significantly different levels when comparing SI (19,647) and LI (18,873) SCs 
to feeders.  This gives us confidence that the SI and LI SCs are phenotypically very different 
from the feeders and that the feeders likely represent a constant background of gene expression 
in both cases. 
 
 
LI 
SI 
 
Figure 10: Heat map indicating differences between SI and LI SCs at a molecular level. Heat Map of 
differentially expressed transcripts in SI versus LI samples. Unsupervised clustering was performed on log2 gene 
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expression values (K-means algorithm) with q<0.05 (FDR=5%) cutoff. Expression values are scaled for minimum 
(blue) and maximum (red) intensity values.  SI and LI samples formed distinct clusters based on cell origin. 
 
4.2 GENES ASSOCIATED WITH PROLIFERATION AND MIGRATION ARE 
AMONG THE MOST SIGNIFICANTLY CHANGED TRANSCRIPTS BETWEEN 
SMALL AND LARGE INTESTINAL SCS AND ARE PREDICTED TO CONTRIBUTE 
TO FUNCTION 
Predictive function analysis predicts the effect that expression changes in the dataset have on 
biological processes and disease. Ingenuity software indicated functional differences in gene 
expression between LI and SI SCs that most frequently appeared in cancer and gastrointestinal 
diseases (Table 6). In the category of cancer, significantly changed genes in epithelial neoplasia 
(301), intestinal cancer (89) and metastasis (55) are predicted to translate to biological function. 
Likewise, functions in gastrointestinal diseases such as digestive organ tumor (127), colorectal 
cancer (88) and metastatic colorectal cancer (24) were among the most significant. Cellular 
development, cellular movement, cellular growth and differentiation and cell-to-cell signaling 
and interaction finish off this selected list among many others with functions in neoplasia of 
tumor cell lines (30), cell movement (142), tumorigenesis of tumor cell lines (20) and binding of 
cells (49). All of these selected functions have a p-value of less than 0.00001. 
 At first glance, it is concerning that so many of the predicted functions are cancer-related. 
However, when considering that cancer is initiated from normal tissue, it follows that shared 
pathways are likely perturbed upon cancer formation. 
 39 
Table 6: Predictive function analysis of 2-fold differentially expressed genes. Genes with fold changes greater 
than or equal to 2 were analyzed in Ingenuity Pathway Analysis (Ingenuity Systems, www.ingenuity.com). The 
functional analysis identified the biological functions and/or diseases that were most significant to the dataset. 
Right-tailed Fisher’s exact test was used to calculate a p-value determining the probability that each biological 
function and/or disease assigned to that dataset is due to chance alone. 
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Category
Functions 
Annotation
p-Value Molecules # Molecules
epithelial 
neoplasia
1.39E-07
ABCA5,ABCC1,ABCC2,ABP1,ACE2,ACP5,ADCY9,AFP,AGR2,AHSG,AKAP13,ALCAM,ALDH8A1,AMACR,A
NPEP,APOBEC1,AREG/AREGB,ARL4C,ATP1B3,BANK1,BBS10,BCHE,BCL11A,BICC1,BMP2K,BPGM,C3,C
6,CADM1,CAPN3,CCND1,CCND2,CCNG2,CD24,CD44,CDH12,CDH2,CDH6,CDK14,CDX2,CEP170,CFB,CH
GA,CHKA,CHST4,CKAP4,CKB,CNTNAP2,COBLL1,COL18A1,COL5A2,CPE,CPS1,CRYL1,CSE1L,CSGALN
ACT2,CTGF,CTSC,CTSL2,CX3CL1,CXCL1,CXCL6,CXCR4,CYP2B6,CYP4F11,CYP51A1,CYR61,DAB2,DAP
K1,DDC,DEFB1,DENND1A,DFNA5,DHRS11,DHRS7,DKK1,DMBT1,DPP4,DPY19L1,DST,DUSP4,DUT,E2F8,
EGF,EHF,ENAH,EPB41L3,ETNK1,ETV5,EXPH5,F2R,FAIM,FAM13A,FAM149A,FAM184A,FAM198B,FAM5C,F
AR2,FARP1,FAS,FCGBP,FGFR2,FOLH1,FOLH1B,FOLR1,FRZB,FXYD3,GALC,GATA4,GCNT1,GDF15,GEM,
GLDC,GLRB,GNAS,GPSM2,GREB1,GSTM1,GUCY2C,HEPH,HES1,HHEX,HIF1A,HK2,HMOX1,HOXC6,HPN
,HRG,HSPA13,HSPB8,HTRA1,ICK,ID4,IFI30,IFI44,IFITM2,IFITM3,IFT81,IGFBP1,IGFBP3,IL6ST,IL8,INSIG1,I
SG20,ITIH2,KCTD14,KIAA1199,KLK10,KRT19,KRT23,KRT7,LAMA4,LAMP3,LCN2,LCT,LEPR,LGALS2,LIMC
H1,LPCAT1,LRP12,LXN,MACF1,MAF,MAOA,MAP4K4,MAX,MCAM,ME1,MEP1A,MGAT4A,MITF,MMP7,MRE
G,MSMO1,MSN,MTUS1,MUC13,MUC5B,MYL9,MYO1A,MYRF,NAAA,NAP1L1,NBN,NCOA1,NDRG2,NEDD9,
NELL2,NME1,NOTCH2,NR2F2,NR5A2,NRP1,NRXN3,NT5E,NTS,OGG1,OSR2,PADI2,PCSK1,PDGFC,PDZK
1IP1,PGAP1,PHLDA1,PID1,PITX2,PLAGL2,PLCE1,PLOD2,PLXNC1,POF1B,PRKAR1A,PRKCH,PRKG2,PRL
R,PRNP,PRODH,PROM1,QPCT,RAB11FIP2,RAMP1,RANBP6,RARRES2,RELN,RPGRIP1L,S100A10,SAA4,
SALL1,SCNN1A,SCRN1,SCUBE2,SEMA5A,SEMA6A,SEPP1,SERPINA3,SERPINA5,SERPINE2,SERPINF1,
SERPING1,SKAP2,SKP2,SLC16A1,SLC16A4,SLC19A2,SLC26A2,SLC26A3,SLC36A1,SLC38A6,SLC39A6,S
LC3A1,SLC44A4,SLC46A3,SLC4A7,SLC5A12,SLC6A8,SLC7A7,SLC7A8,SLC7A9,SLCO1B3,SMARCA2,SN
RPN,SOAT2,SOX4,SPP1,SRPX,STAT1,STC1,SULT1B1,SULT2A1,SYNE2,TACSTD2,TBC1D8,TBL1X,TDP2,
TGFA,TGFB2,TGFBR3,THSD7A,TMEM106C,TMPRSS3,TMX4,TNFAIP2,TNS1,TPM1,TRAM1,TRHDE,TRIM2
2,TSPYL5,TTR,TUBA1A,TUBB6,TUSC3,UGT8,UHRF1BP1L,UNC93A,VAV3,VGLL1,VIPR1,VTCN1,WWTR1,
XK
301
intestinal 
cancer
7.68E-07
ABCA5,ABP1,AKAP13,ALCAM,AMACR,ANPEP,AREG/AREGB,BANK1,CAPN3,CCND1,CCND2,CD24,CD44,
CDH12,CDH2,CDH6,CDX2,CNTNAP2,COBLL1,CRYL1,CSE1L,CTGF,CXCL1,CXCR4,CYR61,DKK1,DPP4,E
GF,ENAH,EPB41L3,F2R,FAS,FCGBP,FGFR2,FOLH1,GATA4,GDF15,GNAS,GPSM2,GREB1,GSTM1,GUCY2
C,HIF1A,HMOX1,HOXC6,HTRA1,IGFBP3,IL8,INSIG1,ISG20,KIAA1199,KLK10,LCN2,LEPR,LGALS2,MAP4K
4,MCAM,MEP1A,MMP7,MUC13,MYO1A,NAAA,NEDD9,NRP1,NTS,PITX2,PLOD2,PRKCH,PRNP,PROM1,Q
PCT,SERPINA3,SERPINE2,SLC16A1,SLC26A2,SLC26A3,SLC38A6,SLCO1B3,SPP1,SRPX,STAT1,TACSTD
2,TDP2,TGFB2,TGFBR3,TNS1,TTR,UGT8,VIPR1
89
metastasis 4.36E-06
AGR2,AHSG,ANPEP,CCND2,CD24,CD44,CD47,CDH2,CDH6,COL18A1,CSE1L,CTGF,CXCL1,CXCL6,CXCR
4,CYR61,DAPK1,DKK1,EGF,ENAH,EPB41L3,F2R,FGFR2,GDF15,GREB1,HIF1A,HMOX1,HOXC6,HRG,HTR
A1,KIAA1199,LCN2,LGALS2,MCAM,MITF,MMP7,NDRG2,NEDD9,NME1,NT5E,PITX2,PLOD2,PRNP,PROM1,
QPCT,RDX,RELN,SLC38A6,SPP1,SRPX,SSX2IP,TGFA,TGFB2,TGFBR3,TUBA1A
55
digestive 
organ tumor
1.87E-07
ABCA5,ABCC1,ABCC2,ABP1,AFP,AKAP13,ALCAM,AMACR,ANPEP,AREG/AREGB,ATP1B3,BANK1,BICC1,
CAP2,CAPN3,CCND1,CCND2,CD24,CD44,CDH12,CDH2,CDH6,CDK14,CDX1,CDX2,CNTNAP2,COBLL1,C
OL18A1,CRYL1,CSE1L,CTGF,CTSC,CTSL2,CXCL1,CXCR4,CYR61,DAPK1,DDC,DKK1,DPP4,E2F8,EGF,EN
AH,EPB41L3,F2R,FAIM,FAS,FCGBP,FGFR2,FOLH1,FXYD3,GATA4,GDF15,GNAS,GPSM2,GREB1,GSTM1,
GUCY2C,HIF1A,HMOX1,HOXC6,HRG,HTRA1,IFT81,IGFBP3,IL8,INSIG1,ISG20,KIAA1199,KLK10,KRT19,K
RT7,LAMA4,LCN2,LEPR,LGALS2,MAOA,MAP4K4,MCAM,MEP1A,MMP7,MTUS1,MUC13,MYO1A,NAAA,NA
MPT,NBN,NEDD9,NME1,NOTCH2,NR5A2,NRP1,NTS,OGG1,PDGFC,PITX2,PLOD2,PRKAR1A,PRKCH,PRN
P,PROM1,QPCT,SAA4,SERPINA3,SERPINE2,SLC16A1,SLC16A4,SLC26A2,SLC26A3,SLC38A6,SLCO1B3,
SOAT2,SOX4,SPP1,SRPX,STAT1,TACSTD2,TDP2,TGFA,TGFB2,TGFBR3,TNS1,TRAM1,TTR,TUBA1A,UGT
8,VIPR1
127
colorectal 
cancer
1.21E-06
ABCA5,ABP1,AKAP13,ALCAM,AMACR,ANPEP,AREG/AREGB,BANK1,CAPN3,CCND1,CCND2,CD24,CD44,
CDH12,CDH2,CDH6,CDX2,CNTNAP2,COBLL1,CRYL1,CSE1L,CTGF,CXCL1,CXCR4,CYR61,DKK1,DPP4,E
GF,ENAH,EPB41L3,F2R,FAS,FCGBP,FGFR2,FOLH1,GATA4,GDF15,GNAS,GPSM2,GREB1,GSTM1,GUCY2
C,HIF1A,HMOX1,HOXC6,HTRA1,IGFBP3,IL8,INSIG1,ISG20,KIAA1199,KLK10,LCN2,LEPR,LGALS2,MAP4K
4,MCAM,MEP1A,MMP7,MUC13,MYO1A,NAAA,NEDD9,NRP1,NTS,PITX2,PLOD2,PRKCH,PRNP,PROM1,Q
PCT,SERPINA3,SERPINE2,SLC16A1,SLC26A2,SLC38A6,SLCO1B3,SPP1,SRPX,STAT1,TACSTD2,TDP2,T
GFB2,TGFBR3,TNS1,TTR,UGT8,VIPR1
88
metastatic 
colorectal 
cancer
9.24E-06
ANPEP,CCND2,CDH2,CDH6,CTGF,DKK1,EPB41L3,F2R,FGFR2,GDF15,GREB1,HMOX1,HOXC6,HTRA1,KI
AA1199,LGALS2,PITX2,PLOD2,PRNP,QPCT,SLC38A6,SRPX,TGFB2,TGFBR3
24
Cellular 
Development
neoplasia of 
tumor cell 
lines
2.30E-08
AREG/AREGB,CCND1,CD24,CDH2,CDX1,CDX2,COL18A1,CSE1L,CXCL1,CXCR4,CYR61,DAPK1,DKK1,D
PP4,E2F8,EGF,F2R,GNAS,HMOX1,IL8,MCAM,NEDD9,NME1,PDZK1IP1,PRKAR1A,PRLR,PRNP,PROM1,SK
P2,STAT1
30
Cellular 
Movement
cell movement 1.57E-06
ABCA1,ABCC1,AGR2,AHSG,ALCAM,ANPEP,AREG/AREGB,BID,C3,C6,CADM1,CCL25,CCND1,CCRL2,CD
24,CD44,CD47,CDH2,CDK14,CDX1,CDX2,CFB,CHGA,CHST4,CKLF,CNTNAP2,COL18A1,CPB2,CSE1L,CT
GF,CTSC,CTSL2,CX3CL1,CXCL1,CXCL5,CXCL6,CXCR4,CYR61,DAB2,DEFB1,DKK1,DMBT1,DPP4,DPYSL
3,DST,EGF,ENAH,ETV5,F2R,FAM5C,FAS,FERMT2,FGFR2,FNDC3B,FOLR1,GALNT1,GCNT1,GDF15,GIP,G
LRB,GNAS,GUCY1B3,HEBP1,HHEX,HIF1A,HMOX1,HRG,HSPB1,HTRA1,IGFBP1,IGFBP3,IL6ST,IL8,KRT19
,LCN2,LGMN,LITAF,MAP4K4,MAX,MCAM,MITF,MMP7,MSN,MYRF,NAMPT,NDP,NDRG2,NEDD9,NEU1,NEU
ROD1,NME1,NOTCH2,NR2F2,NRP1,NT5E,NTS,PITX2,PLXNC1,PRKAR1A,PRLR,PRNP,QPCT,RARRES1,R
ARRES2,RELN,S100A10,SCNN1A,SCPEP1,SDC2,SEMA3E,SEMA5A,SEMA6A,SERPINA3,SERPINA5,SER
PINE2,SERPINF1,SERPING1,SGPP1,SKAP2,SKP2,SLC16A4,SPA17,SPP1,STAT1,STC1,SYNE2,TACSTD2,
TDP2,TGFA,TGFB2,TGFBR3,TNS1,TPBG,TPM1,TSPO,TUBA1A,TUSC3,VAV3,VIPR1,VTCN1,WASF1,WWT
R1
142
Cellular Growth 
and 
Proliferation
tumorigenesis 
of tumor cell 
lines
1.69E-06
AREG/AREGB,CCND1,CD24,CDX1,CDX2,CXCR4,CYR61,DKK1,DPP4,E2F8,EGF,GNAS,IL8,PDZK1IP1,PR
KAR1A,PRLR,PRNP,PROM1,SKP2,STAT1
20
Cell-To-Cell 
Signaling and 
Interaction
binding of 
cells
2.17E-06
ABCA1,ALCAM,AREG/AREGB,C3,CCL25,CD24,CD44,CD47,CDH2,CHST4,CKAP4,COL18A1,CX3CL1,CXC
L1,CXCR4,CYR61,DAPK1,DKK1,DPP4,EGF,F2R,FAS,FERMT2,FOLH1,GCNT1,GNAS,HLA-
DMA,IGFBP3,IL8,LAMA4,LEPR,MSN,NOTCH2,NRP1,NT5E,OXTR,PRNP,RAMP1,RELN,S100A10,SDC2,SE
RPINA5,SERPINF1,SERPING1,SPA17,SPP1,TGFA,TGFB2,VIPR1
49
Cancer
Gastrointestinal 
Disease
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The transcripts with the highest positive fold changes in LI SCs compared to SI SCs were 
related to proliferation, adhesion and migration with known function in cancer and metastasis. A 
few selected molecules were of particular interest. Secreted phosphoprotein 1 (SPP1; better 
known as osteopontin (OPN)) (142-fold increase), CD44 (7-fold increase) and matrix 
metalloproteinase-7 (MMP-7) (37-fold increase) made several appearances in Table 6 with 
functions in epithelial neoplasia, intestinal cancer, metastasis, digestive organ tumor, colorectal 
cancer and cell movement. In our analysis, these three molecules are among those with the 
highest fold changes when comparing LI SCs to SI SCs, indicating a higher likelihood of LI SCs 
to transform over their SI SC counterparts. 
Interestingly, when investigating those transcripts with the highest expression in SI SCs 
compared to LI SCs, the disease-related functions were more limited. Carbamoyl phosphate 1 
(CPS1) showed one of the most dramatically down-regulated expressions (25-fold decrease) in 
LI SCs compared to SI SCs. While it does appear in Table 6 under epithelial neoplasia, it is 
more widely known to be specific for the SI and for its tumor suppressive effects 
120
. Retinoic 
acid receptor responder 1 (RARRES1) (10-fold decrease), as its name suggests, is a retinoid 
regulated gene. Vitamin D, a pro-differentiation agent, induces the expression of RARRES1 and 
a differentiation phenotype in colon cancer cell lines 
121
. Both down- and up-regulated genes 
presented here indicate very different responses and functions of those molecular pathways 
found in LI versus SI SCs. 
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4.3 DIFFERENCES IN THE WNT AND NOTCH PATHWAYS AND SELECTED 
DISEASE RELATION 
Since the Wnt and Notch pathways play such pivotal roles in intestinal homeostasis, we sifted 
through the significantly changed pathway associated transcripts and found an interesting 
pattern. Of the many receptors, intermediaries and targets, we chose twelve Wnt-related 
transcripts that were significantly different between SI and LI SCs (Figure 11). Of those twelve, 
nine of them were upregulated in the LI, indicating Wnt hyperactivity. Other less direct 
regulatory mechanisms may explain the lower expression of some Wnt factors in the LI. 
 Interestingly, four Notch factors were also found to be significantly different between SI 
and LI SCs. Differentiation factors ChrA, ATOH1 and Muc2 indicate a higher degree of 
differentiation in SI SCs while increased Notch2, a receptor for the Notch pathway known to 
play a role in intestinal crypt progenitor cells indicates higher SC activity in LI SCs (Figure 11B) 
63
. Differential responses to the same environment indicate that these are inherited characteristics 
of the different SCs. 
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Figure 11: Wnt and Notch pathway gene expression differences between SI and LI SCs. Histograms 
depict significant (q<0.05) differential expression of individual genes between SI and LI samples classified into 
canonical pathways using Ingenuity Pathways Analysis (see Methods). All values are reported as mean (box) plus 
standard deviation (error bar) of raw intensity for each transcript. The ordinate depicts expression intensity values 
with (A) Wnt Pathway transcripts displayed on 2 graphs with different scale maximum to accurately reflect the 
intrinsic biological range among these samples and (B) Notch pathway participants. FRZB: frizzled-related protein, 
CDH12: cadherin 12, TGFB2: transforming growth factor, beta 2 NR5A2: nuclear receptor subfamily 5, group A, 
member 2, TGFBR3: transforming growth factor, beta receptor III, CDH2: cadherin 2, FZD6: frizzled homolog 6, 
TLE1: transducin-like enhancer of split 1 (E(sp1) homolog, CCND1: cyclin D1, SOX4: SRY (sex determining 
region Y)-box 4, CD44: CD44 molecule (Indian blood group), MMP7: matrix metallopeptidase 7, CHGA: 
chromogranin A, ATOH1: atonal homolog 1, MUC2: Mucin2, NOTCH2: notch 2. 
 
 
Tumor related transcripts indicate that LI SCs may have an inherently greater 
predisposition to form tumors in general and colon tumors in particular compared to SI SCs 
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(Figure 12A). The differential regulation of these molecular pathways may contribute to the 
difference in cancer incidence between SI and LI as well as other intestinal diseases such as 
Crohn’s disease, ulcerative colitis and celiac disease (Figure 12B).  
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Figure 12: Tumor and disease related gene expression differences between SI and LI SCs. Histograms 
depict significant (q<0.05) differential expression of individual genes between SI and LI samples classified into 
canonical pathways using Ingenuity Pathways Analysis (see Methods). All values are reported as mean (box) plus 
standard deviation (error bar) of raw intensity for each transcript. The ordinate depicts expression intensity values 
with (A) Tumor Related transcripts displayed on 2 graphs with different scale maximum to accurately reflect the 
intrinsic biological range among these samples. (B) Intestinal Disease Related genes are those previously thought to 
be involved in either Crohn’s disease, ulcerative colitis or celiac disease. SDCCAG1: serologically defined colon 
cancer antigen 1, IGFBP3: insulin-like growth factor binding protein 3, SPP1: secreted phosphoprotein 1, HIF1A: 
hypoxia inducible factor 1, alpha subunit, PROM1: prominin 1, TACSTD2: tumor-associated calcium signal 
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transducer 2, DLC1: deleted in liver cancer 1, NRP1: neuropilin 1, TP53: tumor protein p53, CDH6: cadherin 6, 
MLH1: mutL homolog 1, VOPP1: vesicular, overexpressed in cancer, prosurvival protein 1, TGFB2: transforming 
growth factor, beta 2, NR5A2: nuclear receptor subfamily 5, group A, member 2, FCGBP: Fc fragment of IgG 
binding protein, HLA-DPB1: major histocompatibility complex, class II, DP beta 1, VAV3: vav 3 guanine 
nucleotide exchange factor, TLE1: transducin-like enhancer of split 1 (E(sp1) homolog, FGFR2: fibroblast growth 
factor receptor 2. 
4.4 DISCUSSION 
Overall, the gene array analysis confirmed that SI and LI SCs have different molecular 
signatures and that they cluster well, but separately from each other (Figure 10). This would be 
expected of total tissue when considering the different structure and function of these two 
segments of the intestine. However, we detected differences in the SCs expanded from the two 
segments, indicating that the information is provided within the different SC populations and 
determines structure and function. 
The predictive function analysis performed in Ingenuity software agreed with past studies 
that normal intestinal SCs share many characteristics with cancer, among them, functions in 
metastasis and cell growth and differentiation 
79, 81
. It is plausible from this and previous data that 
normal SCs may be the origin of LI cancer 
4
.  
The differential expression of the molecules with the highest fold change shows a 
tendency for LI SCs to be more closely related to cancer and possibly more susceptible to cancer 
than their SI SC counterparts. This is particularly evident when considering Wnt and Notch 
pathway participants as well as well-known tumor-related molecules (Figure 11 & Figure 12). 
The Wnt pathway is a diverse and multifactorial pathway that includes cadherins (important for 
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cell-cell interactions), the transforming growth factor beta (TGF family (contributes to 
proliferation and differentiation), cyclin D (CCND1) (drives the G1/S phase of the cell cycle), as 
well as Wnt targets such as CD44 and MMP7, and a Wnt receptor (FZD6). In addition, Sox 4, 
increased here in LI SCs, was found to enhance B-catenin/TCF-LEF activity and proliferation of 
colon cancer cells 
122
. Finally, FRZB (aka SFRP-3), decreased in LI SCs, inhibits Wnt activation 
and acts as a tumor suppressor 
123
. Having a lower expression of a tumor suppressor may 
increase the susceptibility of LI SCs to transformation. 
Many of the tumor-related transcripts in Figure 12 have functions in tumorigenesis and 
cancer cell growth and survival. MutL homolog 1 (MLH1) and p53 are involved in genomic 
stability 
124, 125
 while hypoxia inducible factor 1 (HIF1A) 
126
, vesicular, overexpressed in cancer, 
prosurvival protein 1 (VOPP1) and neuropilin 1 (NRP1) have functions in angiogenesis, cell 
survival and growth. Interestingly, deleted in liver cancer 1 (DLC1) is a tumor suppressor 
127
 that 
is down-regulated in LI SCs, suggesting a higher susceptibility for transformation. Insulin-like 
growth factor binding protein 3 (IGFBP3) is involved in intestinal epithelium homeostasis 
128
. 
An increase of expression in LI SCs indicates differential regulation of homeostatic processes 
between SI and LI SCs. Furthermore, Prom1, also known as CD133, is a well-known CSC 
marker discussed above 
104
. OPN/SPP1 is the transcript with the highest fold change between the 
LI and SI SCs and will be discussed at length below. Two transcripts, serologically defined colon 
cancer antigen 1 (SDCCAG1) and tumor-associated calcium signal transducer 2 (TACSTD2) are 
defined by their presence and association with cancer. From this limited list of the significantly 
different tumor-related transcripts, it is obvious that the SI and LI SCs have intrinsic differences 
regulating these important pathways. 
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Aside from cancer, many of the differentially regulated genes are involved in other 
intestinal-related diseases. Celiac disease, Crohn’s disease and ulcerative colitis plague the 
intestines with uncontrolled inflammation. While these diseases span both the SI and LI we 
found significant differences in several molecules when comparing SI to LI SCs. Transforming 
growth factor- (TGF-increases in the active phase of ulcerative colitis and Crohn’s disease 
129
. Nuclear receptor 5A2 (NR5A2), Fc- binding protein (FCGBP) and fibroblast growth factor 
receptor (FGF) are protective against the development of inflammatory bowel disorders 
40, 130, 131
. 
It is thought that certain HLA-D molecules can even serve as predictors of susceptibility of 
Celiac disease 
132
. Finally transducin-like enhancer of split 1 (TLE1) and vav 3 guanine 
nucleotide exchange factor (Vav3) both play a role in Crohn’s and colitis respectively 133, 134. 
Collectively, the differential expression in SI versus LI SCs may play a role in the susceptibility 
of these two intestinal segments to diseases other than cancer. 
Above, we identified significant differences based on known pathways and diseases of 
the intestine. However, the molecules with the highest fold change between SI and LI SCs define 
functional and relational differences as well as confirm their tissue origin. OPN, with 142-fold 
increase in LI SCs, is thought to have clinical significance in CRC patients. Not only is OPN 
expression higher in CRC cell lines than normal intestinal cell lines, but it is higher in tumor 
tissue in comparison to normal tissue 
135, 136
. It also correlates with lymph node metastasis, 
lymphatic or venous invasion and TNM stage (classification of malignant tumors). Patients with 
a higher expression of OPN had lower 5-year survival rates and it is thought to be an 
independent prognostic factor. Therefore, it may play a role in CRC progression and could be a 
prognostic marker for patients 
136
. In 2003, OPN was identified as the leading candidate clinical 
marker from a screen of approximately 12,000 named genes and later as a marker of tumor 
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progression in CRC 
137, 138
. The protein-protein interaction of OPN and CD44, another transcript 
in the list of highest fold changes, has long been thought to promote metastatic spread 
139
. Some 
have found that CD44 is expressed on hepatocytes and it is through its binding to OPN on CRC 
cells that liver metastasis occurs 
135
. Others have found that CD44 expressing CRC cells, or the 
CSCs of a tumor, enhance the expression and secretion of OPN by tumor-associated 
macrophages (TAM). This expression then promotes CRC cell clonogenicity 
140
. Therefore, OPN 
and CD44 expression are not only associated with metastasis, but also the CSC phenotype and 
poor patient outcomes due to a vicious cycle. CD44 signaling can activate the JNK pathway, 
known for its involvement in not only oncogenic transformation and tumor development, but 
also in its cross-talk with the Wnt pathway and homeostatic control 
141
. Normal control of CD44, 
OPN and the Wnt pathway may be very important in the maintenance of crypt homeostasis in the 
LI as its perturbation has detrimental effects 
139
. Since SI SCs have much less expression of OPN 
and CD44, this balance may be an important homeostatic and protective factor.  
As mentioned earlier, CD44 itself has been implicated in adhesion, migration and CRC 
metastasis 
108, 109
. Our flow panel analysis indicated that normal intestinal SCs in our culture 
system do not express CD44 on their surface. While CD44 has many isoforms, the antibody used 
in this study recognizes all isoforms. However, the gene expression seen in the microarray 
analysis may not be translated into proteins at this stage. While both LI and SI SCs are negative 
for cell surface protein CD44, LI SCs may have a greater propensity to express CD44 at the cell 
surface compared to SI SCs. This poses a dangerous scenario if transformation does occur, 
allowing CD44 transcript translation. 
The last in this group of highly up regulated genes is MMP7. Matrix metalloproteinases 
(MMP) are zinc- or calcium-dependent endopeptidases that degrade matrix glycoproteins. 
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However, it is becoming increasingly known that several members, including MMP-7, are also 
involved in normal cell growth, differentiation and cell regulation. MMP-7 is upregulated in 85% 
of colorectal adenomas and are associated with poor prognosis 
142
. The down regulation of 
MMP-7 caused a subsequent decrease in proliferation and colony formation of colon cancer cells 
as well as an enhanced susceptibility to 5-fluorouracil and X-ray irradiation, indicating the 
promotion of carcinogenesis of colon cancer 
143
. It is thought that MMP-7 may play a role in the 
early stages of CRC because it is a target of beta-catenin/TCF-LEF, downstream of the often-
mutated Wnt pathway member APC 
144, 145
. Interactions have been seen between MMP-7 and the 
genes involved in the pathways of CRC development 
146
. The LI SCs from our culture system 
showed 37-fold higher expression of MMP-7 compared to SI SCs. This higher expression in 
normal cells may make the LI SCs more susceptible to increased proliferation and metastatic 
spread once the initial APC mutation occurs. In addition, if this mutation occurs in normal SCs, 
CSCs will inherit the enhanced drug resistance, a dangerous scenario for patients 
143
. 
On the other hand, the transcripts with the highest negative fold changes when comparing 
LI to SI SCs had much less interesting or well-known functions. CPS1 is a molecule localized to 
the mitochondria that is responsible for the conversion of ammonia to carbamoyl phosphate in 
the urea cycle. This process is limited to hepatocytes and SI enterocytes 
147
. A less well-
understood function is the conversion of arginine into citrulline and nitric oxide (NO), whose 
absence was implicated in the pathophysiology of necrotizing enterocolitis 
148, 149
. Not only can 
CPS1 be a specific marker for SI mucosa, but it is seen to diminish on the pathway from 
adenoma to adenocarcinoma in the SI. 70% of all adenocarcinomas examined had lost CPS1 
expression 
120
. These studies confirm that the intestinal SCs propagated in our culture system are 
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indeed two different SCs, one from the SI, expressing higher amounts of CPS1 and one from the 
LI, expressing lower amounts. 
RARRES1, found here to have low expression in LI SCs, is expressed at high levels in 
the differentiated cells of the normal SI and LI as well as adenomas and well-differentiated 
adenocarcinomas 
150
. Its expression progressively decreases in poorly-differentiated tumors and 
with disease progression. RARRES1 has also been found to reduce invasion and tumorigenicity 
151
. This tumor suppressive role may, in part, explain the 10-fold down-regulation in LI SCs 
compared to SI SCs. Since SI SCs have a higher expression of RARRES1 than LI SCs, they may 
be more protected from transformation and contribute to a lower incidence of SI cancer over LI 
cancer. In addition, a more recent study indicated that RARRES1 might be a controller of SC 
differentiation 
152
. Its higher expression in SI SCs may make them easier to differentiate if a 
transformative event does occur, deeming them less likely to perpetuate a CSC phenotype. 
These expression studies demonstrate a robust examination of the molecular signatures of 
SI and LI SCs. Not only do intrinsic differences between SCs determine structure and function, 
but they also may determine both cancer and other disease susceptibility. 
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5.0  MULTIPOTENTIALITY OF SMALL AND LARGE INTESTINAL STEM CELLS 
Next, because intestinal SCs are defined by their multipotentiality, we investigated the ability of 
intestinal SCs to differentiate into various cell lineages. We adapted a previously defined three-
dimensional culture system to promote SC differentiation in vitro 
5
. This system provides an 
environment that simulates the SC niche and by changing exogenous cues, they respond in 
varying ways. The Matrigel
TM
 matrix provides extracellular matrix proteins such as laminin and 
collagen. Many exogenous factors were added in order to recreate factors normally seen in the 
intestinal crypt (See Methods, Chapter 6.6). R-spondins are known for their enhancement of 
epithelial proliferation as well as their activation of the Wnt pathway as ligands for the LGR 
family of receptors 
153, 154
. Epidermal growth factor (EGF) is involved in intestinal proliferation 
and Noggin in the expansion of crypt numbers 
155, 156
. Nicotinamide, a precursor of oxidized 
nicotinamide adenine dinucleotide that inhibits sirtuin, blocks differentiation 
157
. A83-01, an 
Alk4/5/7 inhibitor and SB202190, a p38 inhibitor, were included to improve plating efficiency 
12
. 
Wnt3A was previously found to cause ISCs to adopt a proliferative progenitor phenotype, 
signifying its importance in the SC media 
158
. By removing Nicotinamide, Wnt3A and 
SB202190, differentiation ensues, thus providing evidence that the cells retain their 
multipotentiality as well as highlight any regulatory differences between SI and LI SC responses. 
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5.1 SMALL AND LARGE INTESTINAL STEM CELLS FORM ORGANOIDS IN 
VITRO 
5.1.1 Small and large intestinal SC organoids differ in morphology 
After expansion on the feeder layer, cells were embedded in Matrigel
TM
 and given media 
containing growth factors known to be important for the proliferation and differentiation of 
intestinal SCs 
12
 (Table 8). Cells were initially plated in Stem Cell (SC) media for 5-10 days. 
After small organoids were established, cells were switched to Differentiation (Diff) media or 
maintained in SC media. After at least 5 days in Diff media, cells were maintained in Diff media 
or supplemented with N-[N-(3,5-difluorophenacetyl)-1-alanyl]-S-phenylglycine t-butyl ester 
(DAPT), a -secretase inhibitor (GSI) (Figure 13A).  Activation of the Notch pathway represses 
secretory cell differentiation 
66
, but inhibition of Notch leads to activation of ATOH1 promoting 
goblet cell differentiation in intestinal crypts and adenomas (see Figure 3) 48, 67. Even though the 
intestinal cells have been removed from their native environment and expanded in vitro, they 
retained the ability to differentiate and form a layer of epithelial cells around a central lumen 
with a similar architecture and cellular hierarchy as found in vivo (Figure 13B compared to 
Figure 4A).  Once the organoids began to grow, they matured rather rapidly, as can be seen in 
daily pictures taken of the same organoids sequentially treated with the three types of media 
(Figure 14). Similar spherical structures were seen for SI and LI in SC media. However, we 
observed morphological differences between the SI and LI SC derived organoids in the Diff and 
Diff+DAPT treatments (Figure 13B & Figure 14). SI structures became more differentiated, with 
the obvious appearance of vacuolated goblet cells in Diff treated organoids and even an 
increased amount with the addition of DAPT. However, LI structures remained spherical without 
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the obvious appearance of goblet cells (Figure 13B). Similarly assayed colon CSCs formed 
structures comparable to the observed LI structures (Figure 15).  
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Figure 13: Three-dimensional differentiation assay for small and large intestinal SCs. (A) Experimental design 
of three-dimensional differentiation assay. Expanded intestinal SCs were embedded as single cells in Matrigel
TM
, 
first expanded in SC media, then treated further with SC media, Differentiation media or Differentiation media + 
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DAPT. (B) In vitro and H&E pictures of organoids from SI and LI SCs in each of the three treatments. One pair of 
SI and LI organoids is representative of three sets examined. Scale bar = 50μm. 
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Figure 14: Daily growth of small and large intestinal organoids. (A) SI organoids grown in SC media, 
Differentiation media and Differentiation media supplemented with DAPT for the last three days. (B) LI organoids 
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grown in SC media, Differentiation media and Differentiation media with DAPT for the last three days. Scale = 
50μm. 
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Figure 15: Colon CSCs form organoids in the differentiation assay. Previously characterized colon 
CSCs (Tu22) 
98
 grown in three-dimensional system form organoids in vitro and can be seen in H&E staining. Scale 
bar = 50μm. 
 
5.1.2 Intestinal organoids harbor a small population of proliferating cells 
As another indication of heterogeneity in the organoids, a modified nucleoside, EdU (5-ethynyl-
2´-deoxyuridine), was used to mark the proliferating cells present in the organoids. This 
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compound is incorporated during DNA synthesis, resulting in a direct measurement of 
proliferating cells. In Figure 16, representative pictures of each treatment group of SI and LI 
intestinal organoids are depicted. Abundant positive cells are present with SC media in both SI 
and LI samples. Upon treatment with either Differentiation media or with the addition of DAPT, 
a dramatic decrease in EdU+ cells was seen (Figure 16A&B). Quantification showed statistically 
significant differences between SC media and both Differentiation and Differentiation + DAPT 
media (Figure 16C).   
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Figure 16: A small subset of cells in intestinal organoids are capable of proliferating and decrease upon 
differentiation cues. Immunofluorescence of EdU+ (red) cells in (A) small and (B) large intestinal organoids in the 
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three treatments. Stained for epithelial marker, EpCAM (green). Counterstain Hoechst 33342 (blue). (C) 
Quantification of percent EdU
+
 cells per total cells for small (left) and large (right) intestinal organoids. Scale = 
50μm. 
 
 
In contrast, when colon CSCs were subjected to EdU treatment, the result showed a 
statistically significant increase in proliferation with each differentiation treatment indicated by 
an increase in the percent of cells that were EdU
+
 (Figure 17A & B). 
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Figure 17: Colon CSC-derived organoids increase percent of proliferating cells with differentiation 
treatment. (A) Immunofluorescence of EdU+ (red) cells in three-dimensional organoids derived from previously 
characterized colon CSCs (Tu25) 
98
 in the three treatments. Stained for EpCAM (green). Counterstain Hoechst 
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33342 (blue). (B) Quantification of percent EdU
+
 cells per total cells for colon CSC-derived organoids. Scale = 
50μm. 
 
 
5.1.3 Small intestinal organoids have more potential for goblet and enteroendocrine cells 
than large intestinal organoids 
Using immunofluorescent staining and quantification of differentiation markers, we analyzed SI 
and LI organoids generated in Matrigel
TM
. The expression of Muc2, a marker of mature goblet 
cells, significantly increased upon Diff and Diff+DAPT treatment in both SI and LI organoids 
(Figure 18). In addition, SI organoids showed increased expression of ChromograninA (ChrA), a 
marker for enteroendocrine cells, with differentiation cues (Figure 18A&C). This phenomenon 
has been observed previously after treatment with a GSI 
159
. However, under the same 
conditions, LI organoids failed to express any measurable amounts of ChrA (Figure 18B).  
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Figure 18: Immunofluorescent staining of intestinal organoids indicating mulitpotentiality and 
response to differentiation cues. (A) SI and (B) LI organoids from paired samples stained for EpCAM (green), 
goblet cell marker, Muc2 (red) and enteroendocrine marker, ChrA (red). Counterstain, Hoechst 33342 (blue). Scale 
bar = 50μm. (C) Quantification of percent goblet or enteroendocrine cells per total cells counted. This paired set 
serves as a representative of two sets examined. 
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A similar phenomenon was also seen in vivo where a significantly higher number of 
ChrA
+
 cells was observed in SI compared to LI (Figure 19).  
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Figure 19: Enteroendocrine cells are found more frequently in the SI than in the LI in vivo. (A) 
Immunofluorescent staining of enteroendocrine cells, ChrA (red), EpCAM (green) in normal human fetal intestine. 
Counterstain, Hoechst 33342 (blue). Scale bar = 50μm. (B) Cells were counted as cells per crypt and depicted in a 
bar graph (*p<0.05 ). 
 
 
Furthermore, enterocyte expression of Villin in SI organoids was lower and dispersed 
throughout the cell but was localized on the cell apical surface in differentiated LI organoids 
(Figure 20).  
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EpCAM / Villin EpCAM / Villin 
EpCAM / Villin EpCAM / Villin 
EpCAM / Villin EpCAM / Villin  
Figure 20: Differential expression of Villin in intestinal organoids. Immunofluorescent staining of SI 
and LI organoids for EpCAM (green) and enterocyte marker, Villin (red). Counterstain, Hoechst 33342 (blue).  
Scale bar = 50μm. 
 
 
Interestingly, Muc2, ChrA and Villin expression in colon CSC organoids resembled that 
of normal LI organoids, with even less expression of all differentiation markers in all treatment 
groups (Figure 21). Less expression of Muc2 is seen in xenograft tumors derived from colon 
CSCs when compared to normal human fetal colon (Figure 22) (not quantified). These data 
provide further evidence that intrinsic differences between human SI and LI SCs regulate their 
differentiation potential and that colon CSCs share more characteristics with normal LI SCs than 
with SI SCs. 
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Figure 21: Immunofluorescence of colon CSCs in differentiation assay. Previously characterized colon CSCs 
(Tu22) 
98
 grown as organized in three-dimensional system and stained for EpCAM (green) goblet cell marker, Muc2 
(red), enteroendocrine marker, ChrA (red) and enterocyte marker, Villin (red). Counterstain, Hoechst 33342 (blue). 
Scale bar = 50μm. 
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Human fetal LI CSC-derived xenograft tumor 
 
Figure 22: Tumor tissue is less differentiated than normal large intestine. Immunofluorescent staining of normal 
human fetal LI and xenograft tumor derived from previously characterized human colon CSCs (Tu22) 
98
 for 
EpCAM (green) and goblet cell marker, Muc2 (red). Counterstain Hoechst 33342 (blue). Scale = 50μm. 
 
5.2 STEM CELL AND DIFFERENTIATION RELATED GENES DIFFER BETWEEN 
SMALL AND LARGE INTESTINAL SC-DERIVED ORGANOIDS 
5.2.1 The Notch pathway is differentially regulated in SI and LI organoids 
Real-time PCR showed increased mRNA expression of ATOH1, Muc2 and ChrA in SI 
organoids upon exposure to differentiation signals (Figure 23A). In LI organoids, Muc2 
expression increased upon exposure to differentiation cues, while ATOH1 and ChrA expression 
was negligible (Figure 23B). This confirmed the absence of ChrA protein expression in LI 
organoids shown in Figure 18. Since ATOH1 is upstream of Muc2, this observation suggests the 
presence of an alternative goblet cell differentiation pathway in LI SCs. These Notch pathway 
differences were also seen in the gene array analysis of LI and SI SCs from two-dimensional 
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cultures, indicating these characteristics are inherited by the different SC populations (Figure 
11B). Interestingly, colon CSC-derived organoids resulted in an increase in Muc2, and even 
small amounts of ChrA transcript expression following differentiation treatment, indicating that 
differentiation pathways remain after transformation (data not shown). 
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Figure 23: The Notch pathway is differentially regulated in SI and LI organoids. Real-time PCR analysis of (A) 
small and (B) large intestinal organoids derived from intestinal SCs and treated with SC media, Differentiation or 
Differentiation media + DAPT. Expression in SC treated organoids was used as control and set to 1. Differentiation 
media and Differentiation media + DAPT expression values are relative to SC media. Expression was normalized to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. Error bars represent upper and lower error limits 
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based on replicate variability (*p<0.05, **p<0.01, ***p<0.001, ns=not significant, # no expression detected). (n=3 
wells per sample/primer pair). One paired SI and LI set serves as a representative of at least two paired sets 
examined. 
 
5.2.2 SC related gene expression differs between SI and LI organoids 
We also found differences in SC related gene expression between Matrigel
TM
 organoids derived 
from SI and LI SCs. As expected, the expression of SC marker and Wnt pathway participant 
LGR5 decreased in SI organoids upon differentiation treatment. Surprisingly, however, LGR5 
reproducibly increased in LI organoids after the addition of Diff media, and only returned to SC 
media levels after treatment with DAPT (Figure 24A & B). This result shows that the SCs of the 
SI and LI have intrinsic differences in their ability to respond to the same environmental cues. 
We also found EphrinB2 (EphB2), another putative intestinal SC marker 
160
, consistently 
increased upon Diff treatment of LI organoids. In SI organoids, EphB2 remained unchanged in 
Diff media but subsequently decreased with the addition of DAPT. In addition, Myc, a Wnt 
target gene, also decreased as expected upon exposure to differentiation cues in SI organoids but 
a significant change in LI organoids was not observed. This confirms the gene array analysis of 
LI and SI SCs expanded in the two-dimensional system displaying significantly different Wnt 
pathway transcript expression with generally more Wnt activity seen in the LI SCs, again 
indicating that these are inherited characteristics of the different SCs (Figure 11A). 
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Figure 24: SC related genes are differentially regulated in SI and LI organoids. Real-time PCR 
analysis of (A) small and (B) large intestinal organoids derived from intestinal SCs and treated with SC media, 
Differentiation or Differentiation media + DAPT. Expression in SC treated organoids was used as control and set to 
1. Differentiation media and Differentiation media + DAPT expression values are relative to SC media. Expression 
was normalized to GAPDH mRNA. Error bars represent upper and lower error limits based on replicate variability 
(*p<0.05, **p<0.01, ***p<0.001, ns=not significant). (n=3 wells per sample/primer pair). One paired SI and LI set 
serves as a representative of at least two paired sets examined. 
 
 
To further understand how colon CSCs compare to normal LI SCs, we also assayed these 
SC related genes in colon CSC-derived organoids (data not shown). In correlation with the LI 
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organoid results, colon CSCs had an increase in LGR5 and EphB2 upon differentiation. Unlike 
their normal counterparts (Figure 24), colon CSC-derived organoids had an increase in Myc 
expression, acting as a tribute to their transformed identity and differential response to 
differentiation cues. 
To better understand the expression differences in genes of interest, we compared SI and 
LI organoids directly at each treatment step and again found undetectable expression of ATOH1 
in LI organoids (Figure 25). LGR5 and Myc were significantly higher in LI organoids compared 
to SI, indicating dramatically different responses in the SCs of the SI and LI (Figure 25). The 
observation that SC and differentiation genes have opposing expression under the same 
environmental cues reveals important differences between the SCs of the SI and LI.  
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Figure 25: Select gene expression in SI versus LI organoids. Real-time PCR analysis of SI and LI organoids 
derived from intestinal SCs and treated with SC media, Differentiation or Differentiation media + DAPT. Select 
marker expression comparison between SI and LI organoids in the three treatments. SI values used as control and set 
to 1. LI expression values are relative to SI. Expression was normalized to GAPDH mRNA. Error bars represent 
upper and lower error limits based on replicate variability (*p<0.05, **p<0.01, ***p<0.001, # no expression 
 70 
detected). (n=3 wells per sample/primer pair). One paired SI and LI set serves as a representative of at least two 
paired sets examined. 
 
 
5.3 DISCUSSION 
SI and LI SCs were subjected to identical sets of environmental stimuli to determine differences 
in differentiation responses. Wnt and Notch factors were carefully controlled in a three-
dimensional system as a way of recreating the intestinal environment and SC niche to allow 
differentiation 
12
. Any differences observed were due to inherent instructions in the cells in 
response to defined exogenous cues. Although both SI and LI organoids responded to 
differentiation treatment with a decrease in proliferation (Figure 15 & Figure 16), morphological 
differences implied that differences did exist (Figure 13 & Figure 14). Further characterization 
confirmed this observation with differential expression of markers for the three cells types in the 
intestine, enterocytes (Villin), goblet cells (Muc2) and enteroendocrine cells (ChrA) (Figure 18 
& Figure 20). Not only does the lack of expression of ChrA in LI organoids highlight an 
important mechanistic difference between the SI and LI, but it also mimicked that which is found 
in vivo, confirming that this in vitro system has provided the cells with an environment similar to 
that found in vivo (Figure 19). The difference in Muc2 expression was initially a concern since 
goblet cells are often more abundant in the LI than the SI. However, upon QPCR analysis, Muc2 
transcript was abundant in LI organoids and increased upon differentiation treatment.  
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Upon differentiation, it is expected that an increase in ATOH1 will lead to an increase in 
Muc2, as part of the Notch pathway 
48
. SI organoids had abundant ATOH1 and Muc2 transcripts, 
however, ATOH1 was not detected in LI organoids, possibly explaining the limited expression 
of Muc2 seen with immunofluorescence. The gene array analysis  (Chapter 4.3) of SI and LI SCs 
indicated that this differentiation pattern is inherited from SCs (Figure 11). The differential 
regulation of the Notch pathway between SI and LI SCs and organoids may reflect a yet 
unknown phenomenon in the LI (Figure 11 & Figure 23). While numerous studies have 
elucidated the many players in the Notch pathway, including ATOH1, most in vivo studies have 
been performed in the SI of mice. As the SI and LI share many characteristics, researchers often 
assume that phenomena seen in the SI would carry into the LI. However, in the current study, 
while the expected results were seen in the SI in all cases, the LI samples followed a different 
pattern, providing reason for caution when classifying the intestines as one organ.  
Interestingly, ATOH1 is important in intestinal cell homeostasis 
161
 and is required for the 
efficacy of GSIs 
162, 163
. This may further explain the limited Muc2 protein expression seen in 
DAPT treated LI organoids. In addition, 70% of CRC patient samples were shown to have 
significantly decreased mRNA expression of ATOH1 compared to tissue-matched normal LI 
samples 
164
. If GSIs require active ATOH1 expression to elicit their differentiation effect, the 
decreased expression of ATOH1 may explain the poor results of differentiation therapies. 
Previous studies also showed that ATOH1 has tumor suppressive effects. Increased expression 
limited tumor cell growth in vitro and loss of expression increased tumor formation in vivo 
164
. 
Therefore, the lack of detectable ATOH1 in LI SC-derived organoids could make them more 
susceptible to transformation than their SI counterparts.  
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Parallel studies in colon CSCs demonstrate an ability to form disorganized organoids 
(Figure 15). When assessing their differentiation capability, it looks as though they have limited 
capability, similar to normal LI organoids. As LI organoids mimic the in vivo structure of the LI, 
organoids derived from CSCs mimic xenograft tumors from the same origin (Figure 21 & Figure 
22). While normal LI tissue is well-organized and follows a defined differentiation pattern, CSC-
derived xenografts are poorly organized with random differentiation patterns throughout the 
tumor tissue. This serves as confirmation that the original characteristics of the cells, normal- or 
cancer-derived have been retained in in vitro organoids. Similarities are expected if mutations in 
normal LI SCs give rise to colon CSCs 
4
.  
Surprisingly, even though the colon CSC-derived organoids showed an increase in Muc2 
expression with differentiation treatment, they also responded with a significant increase in 
proliferation (Figure 17), setting them apart from their untransformed normal LI SC counterparts 
(Figure 16). Although LI SCs seem to have characteristics that would make them more 
susceptible to transformation, there are still well defined controls present, limiting their 
proliferation and inhibiting them from forming tumors (Table 2). CSC-derived organoids not 
only lack these controls, but also have alternate signaling that opposes homeostatic responses 
present in normal tissue. The dramatic increase in proliferation upon differentiation treatment 
may be another reason that GSIs have failed in the clinic. Although many in vitro studies have 
indicated that GSIs increase differentiation 
66
 (as appears in this study as well), when SC and 
proliferation experiments accompany such studies, contradictions arise. Even in the study that 
identified ATOH1 as being required for the effect of GSIs, notch activation and growth 
inhibition seen in human cell lines of CRC were variable 
162
. GSI treatment of wild-type murine 
intestines caused a significant decrease in BrdU incorporation compared to vehicle treated. 
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However, in ATOH1-null mice, there was a significant increase in BrdU incorporation in the LI 
with GSI treatment, demonstrating that loss of ATOH1 can enhance proliferation in response to 
GSIs. This proliferative response was not seen in the SI of ATOH1-null mice. Furthermore, GSI 
treatment of APC
min
 adenoma-bearing mice reduced adenoma proliferation 
67, 162
, but ATOH1 
status was not assessed. Combined with previous results, our study indicates that a lack of 
ATOH1 may be inherited from LI SCs to colon CSCs upon transformation, explaining the 
increased susceptibility of LI SCs to transformation and subsequent failure of GSIs to treat colon 
cancer in the clinic. 
The differences seen between SI and LI organoids extended to the expression of SC 
related genes. EphB2, LGR5 and Myc all decreased in SI organoids upon differentiation 
treatment. However, this general trend was not seen in LI organoids (Figure 24). The differential 
regulation of genes involved in cell proliferation, self-renewal and the Wnt pathway highlight 
key regulatory changes governing SI versus LI determination and likeness to cancer. Quite 
unexpected, LGR5 increased significantly upon differentiation treatment and did not return to SC 
treatment levels until after DAPT treatment. This novel result may reveal a yet unknown 
molecular pathway that distinguishes LI SCs form SI SCs. LGR5 may serve a different role in 
the LI that is not paralleled in the SI. LGR5 was also expressed at a significantly higher level in 
LI versus SI at each treatment step (Figure 25). The higher expression of SC marker LGR5 could 
mean the presence of cells with higher resistance, DNA repair and growth advantage that if 
transformed, could give rise to CSCs ready to rapidly fuel cancer growth 
165
. In fact, CSC-
derived organoids also demonstrated an increase in EphB2 and LGR5 upon differentiation 
treatment, however, this was also accompanied by an increase in Myc. This indicated over 
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activation of the Wnt pathway and suggested again that LI SCs are more susceptible to 
transformation due to their similarities with colon CSCs. 
The expected results obtained from these experiments in SI samples confirm that the 
combined systems of two-dimensional SC expansion and three-dimensional differentiation 
assays reproducibly create an environment similar to that found in vivo. The unexpected results 
seen with the LI samples identify key intrinsic differences between human SI and LI SCs and 
their relation to cancer. 
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6.0  METHODS 
6.1 TISSUE PREPARATION AND CELL CULTURE 
6.1.1 Cell isolation and cell culture 
Small and large intestines were obtained from 19-23 week fetuses from elective abortions 
performed at Magee Women’s Hospital, Pittsburgh, PA. Intestines were cut longitudinally in 
HBSS, contents rinsed, cut into 1-inch pieces, transferred to EBSS/10mM EGTA/1% HEPES 
(Life Technologies, NY/Sigma-Aldrich, MO/Mediatech, VA) and minced. Tissue was then 
transferred to a tube and incubated for 5 min at room temperature. After an EBSS wash, the 
tissue was treated three times with a cocktail containing 1mg/mL collagenase II (Life 
Technologies, NY), 1mg/mL hyaluronidase (Sigma-Aldrich, MO), and 20g/mL DNase I 
(Roche, IN) in HBSS/1% HEPES for 20 min. Tissue/cell suspensions were passed through a 
100m cell strainer (Fisher, PA) to isolate single cells from undigested tissue. Cells were plated 
on irradiated feeders at ~80,000 cells/cm
2
 in DMEM/F12 supplemented with 0.5% FBS, 
25g/mL gentamicin (Sigma-Aldrich, MO), 1% Insulin-Transferrin Selenium (ITS) (Mediatech, 
VA) and 0.1ng/L human R-Spondin2 (R&D, MN).  When single cells were plated, 10M 
ROCK inhibitor, Y-27632 (Reagents Direct, CA), was added to the media for ~24 hours. 
 76 
Cultures were passaged at 2-3 weeks post-plating (~70% confluency) by incubating with 
EBSS/10mM EGTA/1% HEPES followed by 0.25% Trypsin/0.1% EDTA. 
6.1.2 Preparation of feeder cells 
LA7 (ATCC: CRL-2283) cells were grown in DMEM/F12 (Mediatech, VA) supplemented 
with 5% FBS, 1% Pen/Strep (Mediatech, VA), 50nM hydrocortisone (Sigma-Aldrich, MO) and 
5g/mL Insulin (Sigma-Aldrich, MO. Cells were detached from the plate with 0.25% 
Trypsin/0.1% Ethylenediaminetetraacetic acid (EDTA) (Mediatech, VA) and -irradiated at 
17,000 rads. Cell culture flasks were seeded at ~300,000 cells/cm
2
 to generate a confluent 
monolayer of feeder cells. 
6.1.3 Tumor Cell Analysis 
Colon CSCs, originally obtained from tumors surgically removed from the liver of patients with 
metastatic colon cancer, were maintained in the feeder cell system as previously reported 
98
. 
Colon CSCs were subsequently cultured as organoids in matrigel as described above for normal 
intestinal SCs. 
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6.2 XENOGRAFT TUMOR ANALYSIS 
Rag-2/γc-/- mice were anesthetized and transplanted with normal SI and LI SCs or colon CSCs. 
Cells were mixed 1:1 with HBSS/Matrigel and 0.5-1.0e6 cells were injected into the 
subcutaneous space. 1-4 months later, the mice were opened to observe tumor formation. 
 
6.3 GROWTH CURVE ANALYSIS 
Small and large intestinal SCs were assayed for difference in their growth rates using cell culture 
and flow cytometry. Three paired SI and LI samples were independently compared using the 
same number of starting cells on day 0 (SI and LI 1 at 18,750 cells/well, SI and LI 2 and 3 at 
93,750 cells/well) in a 24-well plate seeded with feeder cells. Wells were analyzed in triplicate 
on days 1, 4, 8 and 11 to determine the absolute number of EpCAM+ cells in a defined volume 
using the MACSQuant™ (Mitleyi Biotec, CA) cell analyzer. Triplicates were averaged and 
plotted against time on a line graph to reflect growth rate. A repeated measures ANOVA was 
performed followed by a Student’s t-test. Significance was defined as p<0.05. 
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6.4 MRNA EXPRESSION ASSAYS 
6.4.1 Eukaryotic target preparation 
Total RNA was extracted from frozen cell pellets comprising feeder cells (LA7 feeder cells; n=5) 
and human fetal small or large intestine (SI; n=6 and LI; n=6) putative stem cells. Total RNA 
was isolated using the Qiagen miRNeasy kit (Qiagen Inc., Valencia, CA) according to the 
manufacturer’s protocol. Only RNA of highest quality and integrity was subjected to further 
processing after purification as defined by an absorption ratio 260/280>1.8 obtained by 
spectrophotometry on the NanoDrop 1000 (NanoDrop Inc., Wilmington, DE) and a RIN value 
>8.0 via electrophoretic analysis on the Bioanalyzer 2100 (Agilent Technologies, Santa Clara, 
CA). 
6.4.2 Hybridization 
In vitro transcription (IVT) was performed using the Ambion MessageAmp Premier Enhanced 
assay protocol (Ambion Inc, Austin,
 
TX) starting with 500ng of purified total RNA. 
Confirmation of cRNA
 
diversity was obtained using the Bioanalyzer 2100 to generate
 
an 
electrophoretogram for the products of each IVT reaction regarding sample
 
yield, integrity, and 
size diversity against transcripts derived from a Universal Human Reference RNA (Stratagene,
 
La Jolla, CA). Fifteen micrograms of purified, amplified, biotin labeled cRNA were fragmented 
and hybridized on to Affymetrix Human Genome HGU133A 2.0 arrays (Affymetrix Corp. Santa 
Clara, CA) for 18 hours.  Washing, staining and scanning of arrays was performed on the 
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Affymetrix Fluidics Station 450 and Scanner 3000 immediately after completion of hybridization 
according to the manufacturer’s protocol. 
6.4.3 Data processing 
Microarray data were processed using the Robust Multi-array Average by importing raw CEL 
files into Partek software (Partek Genomics Suite, St. Louis, MO) resulting in RMA background 
correction, log base 2 transformation, quantile normalization, and median polish probe set 
summarization. A 2 way ANOVA was performed across the three groups (LI, SI, LA) versus 
gene expression and post-hoc testing was performed using the Students T test to identify 
transcripts that were significantly changed between groups. A q-value correction adjusted for 
false discovery rate (FDR) was established (q<0.05) to control for Type 1 errors arising from 
multiple tests. Expression data (q value<0.05, 2 fold change) was imported into Ingenuity 
software (Ingenuity Pathways Analysis, Ingenuity Systems Inc, Redwood City, CA) for pathway 
analysis. All figures are plotted using unlogged data to maintain the original biological 
distribution of expression. 
6.5 FLUORESCENCE-ACTIVATED CELL CORTING AND ANALYSIS 
Single cell suspensions were stained with appropriate antibodies (Table 7) at 200,000 cells per 
tube and analyzed on the MACSQuant™ or BD FACSAriaII™ (BD Biosciences, MA). Singlet 
discrimination was performed as described by Wersto et al. 
166
. Post-acquisition analysis was 
carried out in FlowJo (http://www.treestar.com). Staining index was calculated as D/W, where D 
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is the distance between the positive and negative populations and W is two standard deviations 
of the negative population. Limiting Dilution Analyses (LDA) were performed by sorting 1, 10, 
25, 50, 100, 250, 500, 1000 cells per well into respective rows of 96-well plates (Corning, NY) 
seeded with irradiated feeder cells. Plates were counted at four weeks and the number of wells 
with colonies was input into L-Calc (Stem Cell Technologies, Vancouver, BC, Canada). 
 
Table 7: Comprehensive list of antibodies for flow cytometry 
Antibody Manufacturer Concentration 
Epcam-FITC Milteyni Biotec 1:100 
CD24-FITC BD Biosciences 1:50 
CD227FITC BD Biosciences 1:20 
CD49b-FITC BD Biosciences 1:10 
CD49f-FITC BD Biosciences 1:10 
CD34-FITC Milteyni Biotec 1:10 
CD9-FITC BD Biosciences 1:5 
EpCAM-PE Milteyni Biotec 1:50 
CD66c-PE BD Biosciences 1:50 
CD13-PE BD Biosciences 1:25 
CD133.1-PE Milteyni Biotec 1:50 
CD133.2-PE Milteyni Biotec 1:5 
CD166-PE BD Biosciences 1:10 
CD26-PE BD Biosciences 1:5 
EpCAM-APC Milteyni Biotec 1:50 
CD81-APC BD Biosciences 1:10 
CD29-APC BD Biosciences 1:5 
CD90-APC BD Biosciences 1:10 
CD44-APC BD Biosciences 1:10 
CD49f-APC BioLegend 1:10 
CD54-APC BD Biosciences 1:50 
EpCAM-PerCP-Cy5.5 iCyt 1:50 
HLA-Biotin Ancell   1:100 
SAV-APC-Cy7 BD Biosciences 1:25 
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6.6 MATRIGEL DIFFERENTIATION ASSAY AND ANALYSIS 
6.6.1 Culturing in Matrigel 
The differentiation assay was originally found in Sato, et. al. with slight modifications 
12
.  Single 
intestinal cells previously cultured on feeder cells were suspended in 50L Growth Factor 
Reduced (GFR), phenol-red free Matrigel™ (BD Bioscience, CA) and plated in tissue culture 
dishes at low density (~50,000 cells/well of 48-well plate). After solidification at 37C for 30 
min, the matrigel was overlaid with Stem Cell media (SC) (Table 8). For the first 24 hours, the 
media included Y-27632 to prevent anoikis. After initial plating in SC media and the formation 
of small organoids, two-thirds of the wells were switched to Differentiation (Diff) media to allow 
differentiation of the organoids to occur. After further growth of the organoids, DAPT (Reagents 
Direct, CA), a -secretase inhibitor, was added to half the wells containing Diff media at 
10mol/mL for three days. Media was changed on all wells three times a week. Resulting 
organoids were isolated using 0.2% dispase (Life Technologies, NY), 0.1% collagenase II and 
20g/mL DNase I. Organoids were then rinsed in PBS (Mediatech, VA) for downstream 
applications. 
 If DNA synthesis was to be detected after paraffin embedding, EdU (5-ethynyl-2’-
deoxyuridine) (Life Technologies, NY) was added directly to matrigel media at 1M two hours 
prior to collection of organoids.  
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Table 8: List of matrigel media components 
Matrigel media components: Final Conc. Manufacturer SC media Diff Media 
Adv DMEM/F12 1x Life Technologies X X 
Pen/Strep 100/100 U/mL Mediatech X X 
HEPES 10mM Mediatech X X 
N2 1x Life Technologies X X 
B27 1x Life Technologies X X 
Glutamax 2mM Life Technologies X X 
Nacetyl-L-Cysteine 1mM Sigma X X 
[Leu15]-Gastrin I human  Sigma X X 
Y-27632   Reagents Direct X X 
Murine EGF  50ng/mL Peprotech X X 
Human R-Spondin2  0.1ng/L R&D X X 
Noggin  100ng/mL Peprotech X X 
A 83-01 500nM Tocris X X 
Human Wnt-3a  100ng/mL R&D X   
Nicotinamide 10mM Sigma X   
SB 202190  Sigma X   
 
 
6.6.2 Paraffin embedding of matrigel organoids 
Organoids were treated with 4% PFA (Sigma-Aldrich, MO) for 20 min at 4C, rinsed in PBS and 
embedded in 5% gelatin (Sigma-Aldrich, MO) in PBS and solidified on ice for 20 min. The 
gelatin was fixed in 4% PFA for 1 hour at 4C, rinsed in PBS and submitted for paraffin 
embedding. Freshly isolated tissue was fixed in 4% PFA for 2 hours at 4C, rinsed in PBS and 
submitted for paraffin embedding. 
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6.6.3 RNA isolation and quantitative real-time PCR 
Organoids were lysed and RNA isolated using the RNeasy kit (Qiagen, CA). RNA was 
quantified with the Nanodrop (Thermo Scientific, IL). Reverse transcription was performed 
using iScript RT Supermix followed by PCR with SsoADV SYBR Green (Bio-Rad, CA) on an 
ABI StepOne Plus Real-Time PCR machine (Applied Biosystems, CA). Primers were designed 
using Primer Express software (Applied Biosystems, CA) and purchased from Life Technologies 
(NY) (Table 9). Expression was normalized to GAPDH. Error bars represent upper and lower 
error limits based on replicate variability. Statistical analysis was performed using Student’s t-
test (p<0.05 was considered significant). 
 
Table 9: Comprehensive list of real-time PCR primers 
Target Sequence 
ChrA-Fwd CGCTGTCCTGGCTCTTCTG 
ChrA-Rev CCTTTATTCATAGGGCTGTTCACA 
LGR5-Fwd CCTGCGTCTGGATGCTAACC 
LGR5-Rev GGAATGCAGGCCACTGAAA 
Myc-Fwd CGTCTCCACACATCAGCACAA 
Myc-Rev TCTTGGCAGCAGGATAGTCCTT 
Muc2-Fwd TGGCTGGATTCTGGAAAACC 
Muc2-Rev TGGCTCTGCAAGAGATGTTAGC 
ATOH1-Fwd GCAATGTTATCCCGTCGTTCA 
ATOH1-Rev CCATCTGCAGGGTCTCATATTTG 
GAPDH-Fwd GGCATCCTGGGCTACACTGA 
GAPDH-Rev GGAGTGGGTGTCGCTGTTG 
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6.7 IMMUNOFLUORESCENT STAINING 
Antibodies against EpCAM, Chromogranin A, Mucin2 and Villin were used at the appropriate 
dilution in PBS containing 0.5% Bovine Serum Albumin (BSA) (Fisher, PA) (Table 10). Paraffin 
sections were deparaffinized and rehydrated, permeabilized with 0.1% Triton X100 (Sigma-
Aldrich, MO) for 10 min, blocked with 5% BSA for 30 min, stained with primary antibodies for 
one hour followed by either anti-mouse or anti-rabbit Alexa Fluor secondaries (Life 
Technologies, NY) for 30 minutes. Images were taken using an IX71 Inverted microscope 
(Olympus, PA). 
Table 10: Comprehensive list of antibodies for immunofluorescent staining 
Antibody Manufactureer Conentration 
CD133.1 (AC133) Miltenyi Biotech 1:100 
ChrA Millipore 1:400 
Epcam Abcam 1:50 
Lysozyme Novus Biologicals 1:200 
Muc2 Santa Cruz 1:150 
Villin AbD SeroTec 1:100 
Alexa Fluor 488 secondary (anti-Rb) Life Technologies 1:300 
Alexa Fluor 594 secondary (anti-Ms) Life Technologies 1:300 
 
 
For detection of EdU incorporation into cells of matrigel organoids, the Click-iT EdU 
Assay (Life Technologies, NY) was used according to manufacturer’s protocol. In brief, after 
permeabilization as stated above, the sections were rinsed in PBS and incubated for 30 minutes 
with Click-iT reaction cocktail containing the Alexa Fluor 594 azide that reacts with the alkyne 
of EdU to allow detection. The sections were rinsed with Click-iT reaction rinse buffer before 
continuing with blocking and staining with antibodies as noted above. 
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7.0  CONCLUSIONS 
Few methods allow for the expansion of primitive cells from the human intestine. Here 
we have described methods by which to expand primary human SI and LI epithelial SCs. We 
identified the need to alter the culture conditions used previously for the expansion of colon 
CSCs 
98
 by adding a Wnt agonist, R-spondin2, without the evidence of transformation. SI and LI 
SCs were enriched for SC markers CD133.1, CD24, CD166 and CD49f, while being negative for 
CSC marker CD44. We subsequently characterized the cells as having SC characteristics of self-
renewal and differentiation using the two-dimensional SC culture as well as a three-dimensional 
differentiation assay. During this characterization, many differences between SI and LI SCs were 
observed and further analyzed. Initially, both two- and three-dimensional cultures showcased the 
different morphologies of SI and LI cells and their structures, a reflection of their in vivo 
characteristics. Furthermore, CD66c identified two opposing populations in expanded SI and LI 
cells with high self-renewal ability.  
The intricate regulation of the cells was examined by gene array, highlighting the 
differences in proliferation, migration and other disease-related pathways. SI and LI SCs 
clustered well within themselves but very distinct from one another, confirming that their 
differences are rooted in their intrinsic molecular signatures. Notch and Wnt pathway regulation 
revealed differences in fundamental pathways, predicting a higher Wnt activity in LI SCs and a 
more differentiated phenotype in SI SCs. The highest positive fold changes occurred in 
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transcripts with roles in metastasis and CRC progression, while those with the highest negative 
fold changes occurred in transcripts with tumor suppressor roles or an association with a 
differentiation phenotype. These results indicate that LI SCs are more closely related to cancer 
and possibly more susceptible to transformation than SI SCs, owing to the inherent differences in 
LI versus SI SCs.  
Lastly, the organoid differentiation assay confirmed differential regulation of the Notch 
pathway in a system that mimics the in vivo condition. While SI organoids responded as 
expected to environmental changes, LI organoids lacked detectable expression of ATOH1, a key 
player in goblet cell specification. In addition, the dramatic increase in LGR5, the most accepted 
SC marker of the intestine, after differentiation treatment of LI organoids demonstrated a yet 
unobserved phenomenon that may have implications in susceptibility to transformation and 
therapy resistance of transformed cells. 
Many differences between the SI and LI have been observed in recent years, but only one 
study observed differences in SI and LI and attributed it to resident SCs with an implication for 
susceptibility to disease 
167
. This study used a novel label and chase technique to follow intestinal 
SCs over time. These label-retaining cells were absent from the LI and the difference is thought 
to reflect the different functional requirements of the SI and LI as well as their susceptibility to 
cancer. Likewise, the SC marker Bmi1 was mapped to the +4 stem cell position in SI, but was 
absent in LI 
35, 168
. Both of these studies may identify a compensatory SC in the SI that is absent 
in the LI. Without a second SC population, LI SCs receive the full burden of transformative 
insults. However, LI SCs required eight times the dose of irradiation required to reach similar 
levels of apoptosis as their SI SC counterparts, indicating differential responses to a specific type 
of injury 
73
. The increased resistance of LI SCs may be attributed to lower expression of p53 and 
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higher expression of Bcl-2 
72, 74, 75, 169
. When transformation occurs, these resistant behaviors are 
inherited by the newly formed CSCs, fueling a cancer that is difficult to eradicate.  
Our characterization of human fetal SI and LI SCs revealed critical intrinsic differences, 
underscoring the importance of carefully distinguishing between SI and LI, as regulation of 
differentiation and SC pathways show dramatic disparities. This becomes particularly important 
when considering the various models of intestinal cancer that utilize murine small intestine. 
Results derived from such models may not directly correlate to human colon cancer in light of SI 
and LI SC differences reported in this study. These differences may also account for the 
increased prevalence of LI cancer compared to SI cancer, as well as highlight crucial protective 
mechanisms present in the SI that could be exploited to improve the prevention and treatment of 
colon cancer. 
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8.0  FUTURE DIRECTIONS 
The novel characterization in this study comparing human SI and LI SCs in vitro identified many 
important differences that warrant further investigation. 
8.1 ADULT INTESTINAL STEM CELLS 
This study focused solely on the characterization and manipulation of human fetal SI and LI SCs. 
While cancer formation often depicts a return to the developmental state 
170
, making the use of 
fetal cells relevant to cancer studies, colon cancer is very much an old-age disease with the 
highest cancer rates in people aged 75-84 years 
2
. Therefore, it is important to compare the SI 
and LI SCs from adult origin in order to see differences in the SCs that are at risk for 
transformation. Prior to identifying the proper culture conditions for fetal intestinal SCs, attempts 
were made to culture adult intestinal SCs, but without success. Now that the culture conditions 
have been defined, it is likely that they will also aid in the expansion of normal adult intestinal 
SCs.   
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8.2 REGULATION OF APOPTOSIS 
Previous observations have suggested that LI SCs are more resistant to apoptosis in response to 
irradiation 
72, 74, 75
. While this phenomenon was not directly assessed in the current work, the idea 
that LI SCs have high resistance to irradiation may determine the resistance of their transformed 
counterparts, CSCs, to cancer therapies. Therefore, it is important to assess apoptosis in SI and 
LI SCs and determine if there is a specific resistance mechanism present in the LI SCs compared 
to SI SCs. This may be the reason for the higher 5-year survival rate in SI cancers, indicating that 
patients respond more favorably to cancer treatments (Table 1). Higher levels of Bcl-2 and lower 
levels of p53 likely increase the resistance of LI SCs to DNA-damage-induced apoptosis 
72, 74
. 
Their level of expression should be assessed to see if this phenomenon is also true in human 
cells, as previous studies have assessed their role in murine models. If their mechanism of 
resistance can be elucidated, therapies targeting CSCs can be improved. Once the anti-apoptotic 
mechanisms have been identified in normal cells, colon CSCs can be used to assess the efficacy 
of such directed targeting. 
8.3 INTESTINAL REGENERATION AND WOUND HEALING 
Previous studies in mice have indicated that intestinal organoids can be used to heal damaged 
tissue in the intestinal epithelium and promote regeneration 
171
. Therefore, it is important to 
assess if human intestinal SC-derived organoids are capable of the same phenomenon. Wounds 
in the LI of immunocompromised mice could be transplanted with human LI SC-derived 
organoids and compared to the transplantation of SI SC-derived organoids. The detection of 
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engraftment could be aided with the expression of CMV-EGFP in normal SI and LI SCs prior to 
organoid formation. In preliminary studies, we found that LI SCs can be infected with viruses for 
expression purposes. When CMV-EGFP was introduced into LI SCs, EGFP was well 
incorporated and expressed. While it would be interesting to do the same engraftment experiment 
in SI tissue with both SI and LI SC-derived organoids, this would be more technically 
challenging with a higher risk of infection. These experiments would confirm that human 
intestinal SC-derived organoids could help the regeneration of intestinal epithelium after 
damage. 
8.4 LI STEM CELLS VERSUS CSCS 
While the current study focused on the differences between SI and LI SCs, some results 
indicated similarities between LI SCs and colon CSCs. To truly understand what makes a normal 
SC cancerous, comparison studies between the cell of origin and the cell produced must be done. 
For example, results found in this study indicated cell surface expression of CD44 on CSCs but 
absent on normal LI SCs (Figure 7B). It is likely that the overexpression of CD44 protein in 
normal LI SCs may cause the cells to adopt more of a CSC phenotype, assayed by LDA or 
tumorigenicity assays. Alternatively, a reduction in the expression of CD44 in colon CSCs may 
reduce their ability to form colonies or tumors. As mentioned earlier in the text, previous studies 
have shown that a reduction in CD44 lowers the tumorigenicity and clonogenicity of cells in 
vitro 
109
. It is important to confirm this result in CSCs expanded from patients with metastatic 
disease. It is also important to note that according to the gene array results, CD44 transcript is 
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abundant in normal LI SCs, indicating translational repression that may be removed upon 
transformation, allowing the expression of CD44 and enhancement of migration and adhesion. 
8.5 TRANSFORMATION OF NORMAL INTESTINAL STEM CELLS 
Throughout this work, there were many evidences that the normal intestinal SCs expanded in our 
culture system were not transformed. In Chapter 3.1.2 we found that LI and SI SCs did not 
express CD44, while colon CSCs did. In Chapter 2.2.1, we found that the cells are not 
tumorigenic upon transplantation into mice. Lastly, in Chapter 5.1.2 we showed that intestinal 
organoids respond to differentiation cues with a decrease in proliferation, unlike CSC-derived 
organoids that increase their proliferation. If normal LI SCs are the initiating cells of cancer, it 
may be possible to transform them in vitro. Similar to the viral approach used to express CMV-
EGFP, discussed above, virus could be used to introduce a mutated beta-catenin to promote 
transformation, such as beta-catenin with S33A mutation, rendering it stable 
172
. Although 
mutations in beta-catenin are rare in colon cancer, the result is similar to mutations in APC; 
accumulation of beta-catenin in the nucleus with enhanced Wnt signaling 
57
. Alternatively, 
siRNA targeted to APC would also lead to the increased translocation of beta-catenin into the 
nucleus and enhance Wnt signaling. Other components of the Wnt pathway can be targeted 
pharmacologically. GSK3-beta can be catalytically inhibited by CHIR99021, releasing beta-
catenin from the destruction complex 
172
. HLY78 activates Wnt signaling upstream of beta-
catenin by modulating the interaction between Axin-LRP5/6 
173
. These experiments should be 
performed in both SI and LI SCs, with subsequent assessment of changes in proliferation (LDA 
and organoid incorporation of EdU) and response to differentiation cues  (matrigel organoids). 
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However, forced transformation will likely cause transformation in both SI and LI (as in Barker 
2009 
4
), which does not mimic what happens in vivo. From the results presented here, it is the 
increased susceptibility of LI SCs that causes a higher incidence of LI cancer, therefore, 
introducing a forced genetic alteration is likely to result in transformation of both SCs. 
8.6 DETERMINE THE CONSEQUENCES OF MANIPULATING SI AND LI SC 
GENE EXPRESSION 
Significant differences in gene expression were identified in SI and LI SCs, but it is not clear if 
these differences play key roles distinguishing SI from LI SCs and relation to disease. In the 
gene array studies, Chapter 4, expression of OPN and CD44 was found to be higher in LI SCs 
and is linked to metastasis and cancer progression 
139
. High expression of CPS1 and RARRES1 
in SI SCs is linked to differentiation and tumor suppression 
120, 151
. Therefore, if the expression 
patterns were altered using gene knockdown or over expression, the effects could be assessed 
using growth curves, surface marker assessment (CD133.1, CD66c, CD13), LDA and matrigel 
assays. If OPN or CD44 were over expressed or CPS1 or RARRES1 were knocked down in SI 
SCs, we would expect to see an adoption of LI SC characteristics. Likewise, if OPN or CD44 
were knocked down or CPS1 or RARRES1 were over expressed in LI SCs we would expect to 
see an adoption of SI SC characteristics. 
Following the lack of detection of ATOH1 in LI-derived organoids in Chapter 5.2, 
ATOH1 could be expressed in LI-derived organoids. Resulting organoids could be assessed for 
Muc2 and ChrA expression both at RNA and protein levels to see if LI-derived organoids took 
on the phenotype of SI-derived organoids. Likewise, ATOH1 could be knocked down in SI-
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derived organoids and results similarly assessed. LGR5 levels should also be assessed in matrigel 
organoids after changing the expression of ATOH1, since its increase upon differentiation 
treatment of LI-derived organoids (Figure 24B) was an unexpected and yet undocumented 
phenomenon. These experiments would determine if ATOH1 levels are responsible for the 
differences seen in SI- and LI-derived organoids. Subsequently, due to their tumor-suppressor 
roles, ATOH1 and RARRES1 could be knocked down in colon CSCs to see its effect on colony 
formation and tumor formation 
151, 164
. Characterizing the differences between SI and LI SCs and 
CSCs are needed to identify new therapeutic opportunities to improve the prevention and 
treatment of colon cancer. 
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